Combination of (Anti-her3 antibody)-drug conjugate and RASG12c inhibitor

The combination of an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor targets cancer cells with G12C mutations, addressing treatment resistance and enhancing antitumor efficacy by specifically bonding a drug linker to the anti-HER3 antibody for enhanced cancer suppression.

WO2024248123A1PCT designated stage expired Publication Date: 2024-12-05DAIICHI SANKYO CO LTD

Patent Information

Application Number
PCT/JP2024/020005
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current treatments for cancers with KRAS mutations, particularly those involving the G12C mutation, often face resistance and limited efficacy due to aberrant activation of downstream pathways, and there is a need for combination therapies that can effectively suppress cancer cell proliferation.

Method used

A pharmaceutical product combining an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor, where the anti-HER3 antibody is specifically designed with a drug linker bonded via a thioether bond, is administered to target cancer cells, including those with G12C mutations, to enhance antitumor effects.

Benefits of technology

The combination of anti-HER3 antibody-drug conjugate and RASG12C inhibitor exhibits a synergistic effect, significantly suppressing tumor growth in various cancer types, including non-small cell lung cancer, by targeting both HER3 and G12C mutant Ras proteins, thereby overcoming treatment resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024020005_05122024_PF_FP_ABST
    Figure JP2024020005_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention pertains to: a pharmaceutical product comprising an (anti-HER3 antibody)-drug conjugate and a RASG12C inhibitor; and / or a treatment method characterized by administering a combination of an (anti-HER3 antibody)-drug conjugate and a RASG12C inhibitor to a subject.
Need to check novelty before this filing date? Find Prior Art

Description

Combination of anti-HER3 antibody-drug conjugate and RASG12C inhibitor

[0001] The present invention relates to a pharmaceutical product containing an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor, and / or a treatment method characterized in that an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor are administered in combination to a subject.

[0002] Ras proteins are key components of signal transduction pathways that direct cell growth, differentiation, proliferation, and survival. The RAS gene is a frequently mutated oncogene in human cancers, and approximately 30% of all human cancers have mutations in the KRAS, NRAS, or HRAS genes. Oncogenic Ras is associated with mutations at glycine 12, glycine 13, or glutamine 61 of Ras. These residues are located in the active site of Ras, and mutations lead to abnormal activation of downstream effector pathways (MAPK and PI3K pathways). KRAS is the most frequently mutated RAS gene in cancers, with several tumor types showing high frequencies of activating mutations in KRAS, including pancreatic cancer (approximately 90% prevalence); colorectal cancer (approximately 40% prevalence); and non-small cell lung cancer (approximately 30% prevalence). KRAS mutations may be found in other cancer types, including multiple myeloma, uterine cancer, bile duct cancer, gastric cancer, bladder cancer, diffuse large B-cell lymphoma, rhabdomyosarcoma, cutaneous squamous cell carcinoma, cervical cancer, and testicular germ cell cancer (Patent Document 1).

[0003] G12C mutations are commonly found in the RAS gene, accounting for 14% of all KRAS mutations, 2% of all NRAS mutations, and 2% of all HRAS mutations across cancer types. G12C mutations are particularly common in KRAS-mutated non-small cell lung cancer, with approximately half having this mutation. G12C mutations are not only associated with lung cancer, but are also found in other RAS-mutated cancer types, including 8% of all KRAS-mutated colorectal cancers (Patent Document 1).

[0004] Known compounds having inhibitory activity against G12C mutant Ras proteins (RASG12C inhibitors) include, for example, LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553, and JNJ-74699157.

[0005] Human epidermal growth factor receptor 3 (HER3, also known as ErbB3) is a transmembrane receptor belonging to the epidermal growth factor receptor subfamily of receptor protein tyrosine kinases. Increased expression of HER3 in cancer cells is known to be associated with the acquisition of resistance to EGFR-TKIs (Non-Patent Document 1). Studies are also being conducted to verify the effects of anti-HER3 antibodies on non-small cell lung cancer (Non-Patent Document 2).

[0006] Antibody-drug conjugates (ADCs), which are composed of an antibody that binds to an antigen expressed on the surface of cancer cells and that can be internalized into the cells and to which a cytotoxic drug is attached, are expected to be able to selectively deliver drugs to cancer cells, thereby accumulating the drugs within the cancer cells and killing the cancer cells (Non-Patent Documents 3 to 7).

[0007] One known antibody-drug conjugate is one that comprises an anti-HER3 antibody and exatecan, a topoisomerase I inhibitor, as components (Patent Document 2).

[0008] On the other hand, there are no known test results showing the combined effect of the above-mentioned anti-HER3 antibody-drug conjugate and a RASG12C inhibitor, nor any scientific evidence suggesting such test results.

[0009] International Publication No. WO 2020 / 165732 International Publication No. WO 2015 / 155998

[0010] N. V. Sergina et al. Nature 2007 January 25; 445(7126): 437-441. K Yonesaka et al. , Oncogene (2016) 35, 878-886. Ducry, L. , et al. , Bioconjugate Chem. (2010) 21, 5-13. Alley, S. C. , et al. , Current Opinion in Chemical Biology (2010) 14, 529-537. Damle N. K. Expert Opin. Biol. Ther. (2004) 4, 1445-1452. Senter P. D. , et al. , Nature Biotechnology (2012) 30, 631-637. Howard A. et al. , J Clin Oncol 29: 398-405.

[0011] The anti-HER3 antibody-drug conjugate (antibody-drug conjugate containing an exatecan derivative as a component) used in the present invention has been confirmed to exhibit excellent antitumor effects even when used alone. However, it is desirable to develop a treatment method that can demonstrate even more excellent antitumor effects by using it in combination with other anticancer drugs that have different mechanisms of action to comprehensively suppress the proliferation of cancer cells.

[0012] An objective of the present invention is to provide a pharmaceutical product characterized by administering a combination of an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor, and / or a treatment method characterized by administering a combination of an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor to a subject.

[0013] The present inventors have conducted extensive research to solve the above-mentioned problems and have found that administration of an anti-HER3 antibody-drug conjugate in combination with a RASG12C inhibitor provides an excellent combined effect, thereby completing the present invention. That is, in certain embodiments, the present invention provides the following.

[0014] [A1] A pharmaceutical product containing an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor.

[0015] [A2] An anti-HER3 antibody-drug conjugate represented by the formula

[0016]

[0017] (wherein A represents the binding site to the anti-HER3 antibody) and an anti-HER3 antibody are linked via a thioether bond.

[0018] [A3] The pharmaceutical product according to [A1] or [A2], wherein the anti-HER3 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO: 1, CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO: 1, and CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO: 1, and a light chain comprising CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO: 2, CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO: 2, and CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO: 2.

[0019] [A4] The pharmaceutical product according to [A1] or [A2], wherein the anti-HER3 antibody is an antibody comprising a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain comprising a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0020] [A5] The pharmaceutical product according to [A1] or [A2], wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0021] [A6] The pharmaceutical product according to [A5], wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0022] [A7] The pharmaceutical product according to any one of [A1] to [A6], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7 to 8.

[0023] [A8] The pharmaceutical product according to any one of [A1] to [A6], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7.5 to 8.

[0024] [A9] The pharmaceutical product according to any one of [A1] to [A8], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553, and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0025] [A10] The pharmaceutical product according to any one of [A1] to [A8], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0026] [A11] The pharmaceutical product according to any one of [A1] to [A8], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0027] [A12] The pharmaceutical product according to any one of [A1] to [A8], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0028] [A13] The pharmaceutical product according to any one of [A1] to [A12], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained as active ingredients in separate formulations and administered simultaneously or at different times.

[0029] [A14] The pharmaceutical product according to any one of [A1] to [A13], for the treatment of cancer.

[0030] [A15] The pharmaceutical product according to any one of [A1] to [A14], for the treatment of at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0031] [A16] The pharmaceutical product according to [A15] for the treatment of breast cancer.

[0032] [A17] The pharmaceutical product according to [A15] for the treatment of gastric cancer.

[0033] [A18] The pharmaceutical product according to [A15] for the treatment of lung cancer.

[0034] [A19] The pharmaceutical product according to [A18], wherein the lung cancer is non-small cell lung cancer.

[0035] [A20] The pharmaceutical product according to any one of [A1] to [A19], wherein the pharmaceutical product is a pharmaceutical composition.

[0036] [B1] An anti-HER3 antibody-drug conjugate for use in combination with a RASG12C inhibitor for the treatment of cancer.

[0037] [B2] The anti-HER3 antibody-drug conjugate is represented by the formula

[0038]

[0039] (wherein A represents the binding site to the anti-HER3 antibody) and the anti-HER3 antibody are linked via a thioether bond.

[0040] [B3] The antibody-drug conjugate according to [B1] or [B2], wherein the anti-HER3 antibody comprises a heavy chain comprising a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO: 1, a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO: 1, and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO: 1, and a light chain comprising a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO: 2, a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO: 2, and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO: 2.

[0041] [B4] The antibody-drug conjugate according to [B1] or [B2], wherein the anti-HER3 antibody is an antibody comprising a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain comprising a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0042] [B5] The antibody-drug conjugate according to [B1] or [B2], wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0043] [B6] The antibody-drug conjugate according to [B5], wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0044] [B7] The antibody-drug conjugate according to any one of [B1] to [B6], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7 to 8.

[0045] [B8] The antibody-drug conjugate according to any one of [B1] to [B6], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7.5 to 8.

[0046] [B9] The antibody-drug conjugate according to any one of [B1] to [B8], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553, and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0047] [B10] The antibody-drug conjugate according to any one of [B1] to [B8], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0048] [B11] The antibody-drug conjugate according to any one of [B1] to [B8], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0049] [B12] The antibody-drug conjugate according to any one of [B1] to [B8], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0050] [B13] The antibody-drug conjugate according to any one of [B1] to [B12], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained as active ingredients in different formulations, and are administered simultaneously or at different times.

[0051] [B14] The antibody-drug conjugate according to any one of [B1] to [B13], wherein the cancer is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0052] [B15] The antibody-drug conjugate according to [B14], wherein the cancer is breast cancer.

[0053] [B16] The antibody-drug conjugate according to [B14], wherein the cancer is gastric cancer.

[0054] [B17] The antibody-drug conjugate according to [B14], wherein the cancer is lung cancer.

[0055] [B18] The antibody-drug conjugate according to [B17], wherein the lung cancer is non-small cell lung cancer.

[0056] [C1] A RASG12C inhibitor for use in combination with an anti-HER3 antibody-drug conjugate for the treatment of cancer.

[0057] [C2] The anti-HER3 antibody-drug conjugate is represented by the formula

[0058]

[0059] The inhibitor according to [C1], which is an anti-HER3 antibody-drug conjugate in which a drug linker represented by the formula: (wherein A represents the binding site to the anti-HER3 antibody) is bound to the anti-HER3 antibody via a thioether bond.

[0060] [C3] The inhibitor according to [C1] or [C2], wherein the anti-HER3 antibody comprises a heavy chain comprising a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO: 1, a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO: 1, and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO: 1, and a light chain comprising a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO: 2, a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO: 2, and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO: 2.

[0061] [C4] The inhibitor according to [C1] or [C2], wherein the anti-HER3 antibody is an antibody comprising a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain comprising a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0062] [C5] The inhibitor according to [C1] or [C2], wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0063] [C6] The inhibitor according to [C5], wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0064] [C7] The inhibitor according to any one of [C1] to [C6], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7 to 8.

[0065] [C8] The inhibitor according to any one of [C1] to [C6], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7.5 to 8.

[0066] [C9] The inhibitor according to any one of [C1] to [C8], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553 and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0067] [C10] The inhibitor according to any one of [C1] to [C8], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0068] [C11] The inhibitor according to any one of [C1] to [C8], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0069] [C12] The inhibitor according to any one of [C1] to [C8], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0070] [C13] The inhibitor according to any one of [C1] to [C12], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained as active ingredients in different formulations, and are administered simultaneously or at different times.

[0071] [C14] The inhibitor according to any one of [C1] to [C13], wherein the cancer is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0072] [C15] The inhibitor according to [C14], wherein the cancer is breast cancer.

[0073] [C16] The inhibitor according to [C14], wherein the cancer is gastric cancer.

[0074] [C17] The inhibitor according to [C14], wherein the cancer is lung cancer.

[0075] [C18] The inhibitor according to [C17], wherein the lung cancer is non-small cell lung cancer.

[0076] [D1] Use of an anti-HER3 antibody-drug conjugate in combination with a RASG12C inhibitor in the manufacture of a medicament for the treatment of cancer.

[0077] [D2] An anti-HER3 antibody-drug conjugate represented by the formula

[0078]

[0079] (wherein A represents the binding site to the anti-HER3 antibody) and the anti-HER3 antibody are linked via a thioether bond.

[0080] [D3] The use according to [D1] or [D2], wherein the anti-HER3 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO: 1, CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO: 1, and CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO: 1, and a light chain comprising CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO: 2, CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO: 2, and CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO: 2.

[0081] [D4] The use according to [D1] or [D2], wherein the anti-HER3 antibody is an antibody comprising a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain comprising a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0082] [D5] The use according to [D1] or [D2], wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0083] [D6] The use according to [D5], wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0084] [D7] The use according to any one of [D1] to [D6], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7 to 8.

[0085] [D8] The use according to any one of [D1] to [D6], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7.5 to 8.

[0086] [D9] The use according to any one of [D1] to [D8], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553, and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0087] [D10] The use according to any one of [D1] to [D8], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0088] [D11] The use according to any one of [D1] to [D8], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0089] [D12] The use according to any one of [D1] to [D8], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0090] [D13] The use according to any one of [D1] to [D12], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained as active ingredients in different formulations, and are administered simultaneously or at different times.

[0091] [D14] The use according to any one of [D1] to [D13], wherein the cancer is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0092] [D15] The use according to [D14], wherein the cancer is breast cancer.

[0093] [D16] The use according to [D14], wherein the cancer is gastric cancer.

[0094] [D17] The use according to [D14], wherein the cancer is lung cancer.

[0095] [D18] The use according to [D17], wherein the lung cancer is non-small cell lung cancer.

[0096] [E1] A method for treating a disease, comprising administering an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor in combination to a subject in need of treatment.

[0097] [E2] The anti-HER3 antibody-drug conjugate is represented by the formula

[0098]

[0099] (wherein A represents the binding site to the anti-HER3 antibody) and the anti-HER3 antibody are linked via a thioether bond.

[0100] [E3] The treatment method according to [E1] or [E2], wherein the anti-HER3 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO: 1, CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO: 1, and CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO: 1, and a light chain comprising CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO: 2, CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO: 2, and CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO: 2.

[0101] [E4] The treatment method described in [E1] or [E2], wherein the anti-HER3 antibody is an antibody comprising a heavy chain including a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain including a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0102] [E5] The treatment method according to [E1] or [E2], wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0103] [E6] The treatment method according to [E5], wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0104] [E7] The method of treatment according to any one of [E1] to [E6], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7 to 8.

[0105] [E8] The method of treatment according to any one of [E1] to [E6], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7.5 to 8.

[0106] [E9] The method for treatment according to any one of [E1] to [E8], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553, and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0107] [E10] The method of treatment according to any one of [E1] to [E8], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0108] [E11] The method of treatment according to any one of [E1] to [E8], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0109] [E12] The method of treatment according to any one of [E1] to [E8], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0110] [E13] The method of treatment according to any one of [E1] to [E12], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained as active ingredients in different formulations, and are administered simultaneously or at different times.

[0111] [E14] The method of treatment according to any one of [E1] to [E13], wherein the disease is cancer.

[0112] [E15] The method of treatment according to any one of [E1] to [E14], wherein the disease is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0113] [E16] The method of treatment according to [E15], wherein the disease is breast cancer.

[0114] [E17] The method of treatment according to [E15], wherein the disease is gastric cancer.

[0115] [E18] The method of treatment according to [E15], wherein the disease is lung cancer.

[0116] [E19] The method of treatment according to [E18], wherein the lung cancer is non-small cell lung cancer.

[0117] [A1-1] A pharmaceutical product containing an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor.

[0118] [A2-1] An anti-HER3 antibody-drug conjugate represented by the formula

[0119]

[0120] (wherein A represents the binding site to the anti-HER3 antibody or a functional fragment thereof) and an anti-HER3 antibody or a functional fragment thereof via a thioether bond.

[0121] [A3-1] The pharmaceutical product according to [A1-1] or [A2-1], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO: 1; a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO: 1; and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO: 1; and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO: 2; a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO: 2; and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO: 2.

[0122] [A4-1] The pharmaceutical product according to [A1-1] or [A2-1], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0123] [A5-1] The pharmaceutical product according to [A1-1] or [A2-1], wherein the anti-HER3 antibody is an antibody or a functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0124] [A6-1] The pharmaceutical product according to [A5-1], wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0125] [A7-1] The pharmaceutical product according to any one of [A1-1] to [A6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 2 to 8.

[0126] [A8-1] The pharmaceutical product according to any one of [A1-1] to [A6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 3 to 8.

[0127] [A9-1] The pharmaceutical product according to any one of [A1-1] to [A6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7 to 8.

[0128] [A10-1] The pharmaceutical product according to any one of [A1-1] to [A6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7.5 to 8.

[0129] [A11-1] The pharmaceutical product according to any one of [A1-1] to [A6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is 8.

[0130] [A12-1] The pharmaceutical product according to any one of [A1-1] to [A11-1], wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

[0131] [A13-1] The pharmaceutical product according to any one of [A1-1] to [A12-1], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553 and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0132] [A14-1] The pharmaceutical product according to any one of [A1-1] to [A12-1], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0133] [A15-1] The pharmaceutical product according to any one of [A1-1] to [A12-1], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0134] [A16-1] The pharmaceutical product according to any one of [A1-1] to [A12-1], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0135] [A17-1] The pharmaceutical product according to any one of [A1-1] to [A16-1], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained (as active ingredients) in separate formulations and administered simultaneously or at different times.

[0136] [A18-1] A pharmaceutical product according to any one of [A1-1] to [A17-1] for the treatment of cancer.

[0137] [A19-1] The pharmaceutical product according to any one of [A1-1] to [A18-1], for the treatment of at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0138] [A20-1] The pharmaceutical product according to [A19-1] for the treatment of breast cancer.

[0139] [A21-1] The pharmaceutical product according to [A19-1] for the treatment of gastric cancer.

[0140] [A22-1] The pharmaceutical product according to [A19-1] for the treatment of lung cancer.

[0141] [A23-1] The pharmaceutical product according to [A22-1], wherein the lung cancer is non-small cell lung cancer.

[0142] [A24-1] The pharmaceutical product according to any one of [A1-1] to [A23-1], wherein the pharmaceutical product is a pharmaceutical composition.

[0143] [B1-1] An anti-HER3 antibody-drug conjugate for use in combination with a RASG12C inhibitor for the treatment of cancer.

[0144] [B2-1] An anti-HER3 antibody-drug conjugate represented by the formula

[0145]

[0146] (wherein A represents the binding site to the anti-HER3 antibody or a functional fragment thereof) and the anti-HER3 antibody or a functional fragment thereof via a thioether bond.

[0147] [B3-1] The antibody-drug conjugate according to [B1-1] or [B2-1], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO: 1; a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO: 1; and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO: 1; and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO: 2; a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO: 2; and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO: 2.

[0148] [B4-1] The antibody-drug conjugate according to [B1-1] or [B2-1], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0149] [B5-1] The antibody-drug conjugate according to [B1-1] or [B2-1], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0150] [B6-1] The antibody-drug conjugate according to [B5-1], wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0151] [B7-1] The antibody-drug conjugate according to any one of [B1-1] to [B6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 2 to 8.

[0152] [B8-1] The antibody-drug conjugate according to any one of [B1-1] to [B6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 3 to 8.

[0153] [B9-1] The antibody-drug conjugate according to any one of [B1-1] to [B6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7 to 8.

[0154] [B10-1] The antibody-drug conjugate according to any one of [B1-1] to [B6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7.5 to 8.

[0155] [B11-1] The antibody-drug conjugate according to any one of [B1-1] to [B6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is 8.

[0156] [B12-1] The antibody-drug conjugate according to any one of [B1-1] to [B11-1], wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

[0157] [B13-1] The antibody-drug conjugate according to any one of [B1-1] to [B12-1], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553, and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0158] [B14-1] The antibody-drug conjugate according to any one of [B1-1] to [B12-1], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0159] [B15-1] The antibody-drug conjugate according to any one of [B1-1] to [B12-1], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0160] [B16-1] The antibody-drug conjugate according to any one of [B1-1] to [B12-1], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0161] [B17-1] The antibody-drug conjugate according to any one of [B1-1] to [B16-1], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained (as active ingredients) in different formulations and administered simultaneously or at different times.

[0162] [B18-1] The antibody-drug conjugate according to any one of [B1-1] to [B17-1], wherein the cancer is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0163] [B19-1] The antibody-drug conjugate according to [B18-1], wherein the cancer is breast cancer.

[0164] [B20-1] The antibody-drug conjugate according to [B18-1], wherein the cancer is gastric cancer.

[0165] [B21-1] The antibody-drug conjugate according to [B18-1], wherein the cancer is lung cancer.

[0166] [B22-1] The antibody-drug conjugate according to [B21-1], wherein the lung cancer is non-small cell lung cancer.

[0167] [C1-1] A RASG12C inhibitor for use in combination with an anti-HER3 antibody-drug conjugate for the treatment of cancer.

[0168] [C2-1] An anti-HER3 antibody-drug conjugate represented by the formula

[0169]

[0170] (wherein A represents the binding site to the anti-HER3 antibody or a functional fragment thereof) and an anti-HER3 antibody or a functional fragment thereof via a thioether bond.

[0171] [C3-1] The inhibitor according to [C1-1] or [C2-1], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 in SEQ ID NO: 1; CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 in SEQ ID NO: 1; and CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 in SEQ ID NO: 1; and CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 in SEQ ID NO: 2; CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 in SEQ ID NO: 2; and CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 in SEQ ID NO: 2.

[0172] [C4-1] The inhibitor according to [C1-1] or [C2-1], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0173] [C5-1] The inhibitor according to [C1-1] or [C2-1], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0174] [C6-1] The inhibitor according to [C5-1], wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0175] [C7-1] The inhibitor according to any one of [C1-1] to [C6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 2 to 8.

[0176] [C8-1] The inhibitor according to any one of [C1-1] to [C6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 3 to 8.

[0177] [C9-1] The inhibitor according to any one of [C1-1] to [C6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7 to 8.

[0178] [C10-1] The inhibitor according to any one of [C1-1] to [C6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7.5 to 8.

[0179] [C11-1] The inhibitor according to any one of [C1-1] to [C6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is 8.

[0180] [C12-1] The inhibitor according to any one of [C1-1] to [C11-1], wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

[0181] [C13-1] The inhibitor according to any one of [C1-1] to [C12-1], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553 and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0182] [C14-1] The inhibitor according to any one of [C1-1] to [C12-1], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0183] [C15-1] The inhibitor according to any one of [C1-1] to [C12-1], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0184] [C16-1] The inhibitor according to any one of [C1-1] to [C12-1], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0185] [C17-1] The inhibitor according to any one of [C1-1] to [C16-1], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained (as active ingredients) in different formulations, and are administered simultaneously or at different times.

[0186] [C18-1] The inhibitor according to any one of [C1-1] to [C17-1], wherein the cancer is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0187] [C19-1] The inhibitor according to [C18-1], wherein the cancer is breast cancer.

[0188] [C20-1] The inhibitor according to [C18-1], wherein the cancer is gastric cancer.

[0189] [C21-1] The inhibitor according to [C18-1], wherein the cancer is lung cancer.

[0190] [C22-1] The inhibitor according to [C21-1], wherein the lung cancer is non-small cell lung cancer.

[0191] [D1-1] Use of an anti-HER3 antibody-drug conjugate in combination with a RASG12C inhibitor in the manufacture of a medicament for the treatment of cancer.

[0192] [D2-1] An anti-HER3 antibody-drug conjugate represented by the formula

[0193]

[0194] (wherein A represents the binding site to the anti-HER3 antibody or a functional fragment thereof) and the anti-HER3 antibody or a functional fragment thereof are linked via a thioether bond.

[0195] [D3-1] The use according to [D1-1] or [D2-1], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO: 1; a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO: 1; and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO: 1; and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO: 2; a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO: 2; and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO: 2.

[0196] [D4-1] The use according to [D1-1] or [D2-1], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0197] [D5-1] The use according to [D1-1] or [D2-1], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0198] [D6-1] The use according to [D5-1], wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0199] [D7-1] The use according to any one of [D1-1] to [D6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 2 to 8.

[0200] [D8-1] The use according to any one of [D1-1] to [D6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 3 to 8.

[0201] [D9-1] The use according to any one of [D1-1] to [D6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7 to 8.

[0202] [D10-1] The use according to any one of [D1-1] to [D6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7.5 to 8.

[0203] [D11-1] The use according to any one of [D1-1] to [D6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is 8.

[0204] [D12-1] The use according to any one of [D1-1] to [D11-1], wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

[0205] [D13-1] The use according to any one of [D1-1] to [D12-1], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553, and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0206] [D14-1] The use according to any one of [D1-1] to [D12-1], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0207] [D15-1] The use according to any one of [D1-1] to [D12-1], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0208] [D16-1] The use according to any one of [D1-1] to [D12-1], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0209] [D17-1] The use according to any one of [D1-1] to [D16-1], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained (as active ingredients) in different formulations and administered simultaneously or at different times.

[0210] [D18-1] The use according to any one of [D1-1] to [D17-1], wherein the cancer is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0211] [D19-1] The use according to [D18-1], wherein the cancer is breast cancer.

[0212] [D20-1] The use according to [D18-1], wherein the cancer is gastric cancer.

[0213] [D21-1] The use according to [D18-1], wherein the cancer is lung cancer.

[0214] [D22-1] The use according to [D21-1], wherein the lung cancer is non-small cell lung cancer.

[0215] [E1-1] A method for treating a disease, comprising administering a combination of an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor to a subject in need of treatment.

[0216] [E2-1] An anti-HER3 antibody-drug conjugate represented by the formula

[0217]

[0218] (wherein A represents the binding site to the anti-HER3 antibody or a functional fragment thereof) and the anti-HER3 antibody or a functional fragment thereof are linked via a thioether bond.

[0219] [E3-1] The treatment method according to [E1-1] or [E2-1], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO: 1; CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO: 1; and CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO: 1; and CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO: 2; CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO: 2; and CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO: 2.

[0220] [E4-1] The treatment method described in [E1-1] or [E2-1], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0221] [E5-1] The treatment method described in [E1-1] or [E2-1], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0222] [E6-1] The therapeutic method according to [E5-1], wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.

[0223] [E7-1] The treatment method according to any one of [E1-1] to [E6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 2 to 8.

[0224] [E8-1] The treatment method according to any one of [E1-1] to [E6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 3 to 8.

[0225] [E9-1] The treatment method according to any one of [E1-1] to [E6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7 to 8.

[0226] [E10-1] The treatment method according to any one of [E1-1] to [E6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7.5 to 8.

[0227] [E11-1] The method of treatment according to any one of [E1-1] to [E6-1], wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is 8.

[0228] [E12-1] The treatment method according to any one of [E1-1] to [E11-1], wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

[0229] [E13-1] The method for treatment according to any one of [E1-1] to [E12-1], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553 and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0230] [E14-1] The method of treatment according to any one of [E1-1] to [E12-1], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0231] [E15-1] The method of treatment according to any one of [E1-1] to [E12-1], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0232] [E16-1] The method of treatment according to any one of [E1-1] to [E12-1], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0233] [E17-1] The method of treatment according to any one of [E1-1] to [E16-1], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained (as active ingredients) in different formulations and administered simultaneously or at different times.

[0234] [E18-1] The method of treatment according to any one of [E1-1] to [E17-1], wherein the disease is cancer.

[0235] [E19-1] The method of treatment according to any one of [E1-1] to [E18-1], wherein the disease is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0236] [E20-1] The method of treatment according to [E19-1], wherein the disease is breast cancer.

[0237] [E21-1] The method of treatment according to [E19-1], wherein the disease is gastric cancer.

[0238] [E22-1] The method of treatment according to [E19-1], wherein the disease is lung cancer.

[0239] [E23-1] The method of treatment according to [E22-1], wherein the lung cancer is non-small cell lung cancer.

[0240] [A1-2] A pharmaceutical product containing an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor.

[0241] [A2-2] An anti-HER3 antibody-drug conjugate represented by the formula

[0242]

[0243] (wherein the formula is an anti-HER3 antibody or a functional fragment thereof, the drug linker is bound to the antibody or the functional fragment thereof via a thioether bond, and n is a drug-to-antibody ratio.) The pharmaceutical product according to [A1-2],

[0244] [A3-2] The pharmaceutical product according to [A1-2] or [A2-2], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO: 1; a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO: 1; and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO: 1; and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO: 2; a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO: 2; and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO: 2.

[0245] [A4-2] The pharmaceutical product according to [A1-2] or [A2-2], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0246] [A5-2] The pharmaceutical product according to [A1-2] or [A2-2], wherein the anti-HER3 antibody is an antibody or a functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0247] [A6-2] The pharmaceutical product according to [A5-2], in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0248] [A7-2] The pharmaceutical product according to any one of [A1-2] to [A6-2], wherein n is 2 to 8.

[0249] [A8-2] The pharmaceutical product according to any one of [A1-2] to [A6-2], wherein n is 3 to 8.

[0250] [A9-2] The pharmaceutical product according to any one of [A1-2] to [A6-2], wherein n is 7 to 8.

[0251] [A10-2] The pharmaceutical product according to any one of [A1-2] to [A6-2], wherein n is 7.5 to 8.

[0252] [A11-2] The pharmaceutical product according to any one of [A1-2] to [A6-2], wherein n is 8.

[0253] [A12-2] The pharmaceutical product according to any one of [A1-2] to [A11-2], wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

[0254] [A13-2] The pharmaceutical product according to any one of [A1-2] to [A12-2], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553 and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0255] [A14-2] The pharmaceutical product according to any one of [A1-2] to [A12-2], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0256] [A15-2] The pharmaceutical product according to any one of [A1-2] to [A12-2], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0257] [A16-2] The pharmaceutical product according to any one of [A1-2] to [A12-2], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0258] [A17-2] The pharmaceutical product according to any one of [A1-2] to [A16-2], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained (as active ingredients) in separate formulations and administered simultaneously or at different times.

[0259] [A18-2] A pharmaceutical product according to any one of [A1-2] to [A17-2] for the treatment of cancer.

[0260] [A19-2] The pharmaceutical product according to any one of [A1-2] to [A18-2], for the treatment of at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0261] [A20-2] The pharmaceutical product according to [A19-2] for the treatment of breast cancer.

[0262] [A21-2] The pharmaceutical product according to [A19-2] for the treatment of gastric cancer.

[0263] [A22-2] The pharmaceutical product according to [A19-2] for the treatment of lung cancer.

[0264] [A23-2] The pharmaceutical product according to [A22-2], wherein the lung cancer is non-small cell lung cancer.

[0265] [A24-2] The pharmaceutical product according to any one of [A1-2] to [A23-2], wherein the pharmaceutical product is a pharmaceutical composition.

[0266] [B1-2] An anti-HER3 antibody-drug conjugate for use in combination with a RASG12C inhibitor for the treatment of cancer.

[0267] [B2-2] An anti-HER3 antibody-drug conjugate represented by the formula

[0268]

[0269] (wherein "anti-HER3 antibody" is an anti-HER3 antibody or a functional fragment thereof, the drug linker is bound to the antibody or a functional fragment thereof via a thioether bond, and n is a drug-to-antibody ratio).

[0270] [B3-2] The antibody-drug conjugate according to [B1-2] or [B2-2], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO: 1; a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO: 1; and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO: 1; and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO: 2; a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO: 2; and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO: 2.

[0271] [B4-2] The antibody-drug conjugate according to [B1-2] or [B2-2], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0272] [B5-2] The antibody-drug conjugate according to [B1-2] or [B2-2], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0273] [B6-2] The antibody-drug conjugate according to [B5-2], wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0274] [B7-2] The antibody-drug conjugate according to any one of [B1-2] to [B6-2], wherein n is 2 to 8.

[0275] [B8-2] The antibody-drug conjugate according to any one of [B1-2] to [B6-2], wherein n is 3 to 8.

[0276] [B9-2] The antibody-drug conjugate according to any one of [B1-2] to [B6-2], wherein n is 7 to 8.

[0277] [B10-2] The antibody-drug conjugate according to any one of [B1-2] to [B6-2], wherein n is 7.5 to 8.

[0278] [B11-2] The antibody-drug conjugate according to any one of [B1-2] to [B6-2], wherein n is 8.

[0279] [B12-2] The antibody-drug conjugate according to any one of [B1-2] to [B11-2], wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

[0280] [B13-2] The antibody-drug conjugate according to any one of [B1-2] to [B12-2], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553, and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0281] [B14-2] The antibody-drug conjugate according to any one of [B1-2] to [B12-2], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0282] [B15-2] The antibody-drug conjugate according to any one of [B1-2] to [B12-2], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0283] [B16-2] The antibody-drug conjugate according to any one of [B1-2] to [B12-2], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0284] [B17-2] The antibody-drug conjugate according to any one of [B1-2] to [B16-2], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained (as active ingredients) in different formulations and administered simultaneously or at different times.

[0285] [B18-2] The antibody-drug conjugate according to any one of [B1-2] to [B17-2], wherein the cancer is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0286] [B19-2] The antibody-drug conjugate according to [B18-2], wherein the cancer is breast cancer.

[0287] [B20-2] The antibody-drug conjugate according to [B18-2], wherein the cancer is gastric cancer.

[0288] [B21-2] The antibody-drug conjugate according to [B18-2], wherein the cancer is lung cancer.

[0289] [B22-2] The antibody-drug conjugate according to [B21-2], wherein the lung cancer is non-small cell lung cancer.

[0290] [C1-2] A RASG12C inhibitor for use in combination with an anti-HER3 antibody-drug conjugate for the treatment of cancer.

[0291] [C2-2] An anti-HER3 antibody-drug conjugate represented by the formula

[0292]

[0293] (wherein "anti-HER3 antibody" is an anti-HER3 antibody or a functional fragment thereof, the drug linker is bound to the antibody or the functional fragment thereof via a thioether bond, and n is a drug-to-antibody ratio).

[0294] [C3-2] The inhibitor according to [C1-2] or [C2-2], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 in SEQ ID NO: 1; a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 in SEQ ID NO: 1; and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 in SEQ ID NO: 1; and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 in SEQ ID NO: 2; a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 in SEQ ID NO: 2; and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 in SEQ ID NO: 2.

[0295] [C4-2] The inhibitor according to [C1-2] or [C2-2], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0296] [C5-2] The inhibitor according to [C1-2] or [C2-2], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0297] [C6-2] The inhibitor according to [C5-2], wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0298] [C7-2] The inhibitor according to any one of [C1-2] to [C6-2], wherein n is 2 to 8.

[0299] [C8-2] The inhibitor according to any one of [C1-2] to [C6-2], wherein n is 3 to 8.

[0300] [C9-2] The inhibitor according to any one of [C1-2] to [C6-2], wherein n is 7 to 8.

[0301] [C10-2] The inhibitor according to any one of [C1-2] to [C6-2], wherein n is 7.5 to 8.

[0302] [C11-2] The inhibitor according to any one of [C1-2] to [C6-2], wherein n is 8.

[0303] [C12-2] The inhibitor according to any one of [C1-2] to [C11-2], wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

[0304] [C13-2] The inhibitor according to any one of [C1-2] to [C12-2], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553 and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0305] [C14-2] The inhibitor according to any one of [C1-2] to [C12-2], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0306] [C15-2] The inhibitor according to any one of [C1-2] to [C12-2], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0307] [C16-2] The inhibitor according to any one of [C1-2] to [C12-2], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0308] [C17-2] The inhibitor according to any one of [C1-2] to [C16-2], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained (as active ingredients) in different formulations and administered simultaneously or at different times.

[0309] [C18-2] The inhibitor according to any one of [C1-2] to [C17-2], wherein the cancer is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0310] [C19-2] The inhibitor according to [C18-2], wherein the cancer is breast cancer.

[0311] [C20-2] The inhibitor according to [C18-2], wherein the cancer is gastric cancer.

[0312] [C21-2] The inhibitor according to [C18-2], wherein the cancer is lung cancer.

[0313] [C22-2] The inhibitor according to [C21-2], wherein the lung cancer is non-small cell lung cancer.

[0314] [D1-2] Use of an anti-HER3 antibody-drug conjugate in combination with a RASG12C inhibitor in the manufacture of a medicament for the treatment of cancer.

[0315] [D2-2] An anti-HER3 antibody-drug conjugate represented by the formula

[0316]

[0317] (wherein "anti-HER3 antibody" is an anti-HER3 antibody or a functional fragment thereof, the drug linker is bound to the antibody or the functional fragment thereof via a thioether bond, and n is a drug-to-antibody ratio).

[0318] [D3-2] The use according to [D1-2] or [D2-2], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO: 1; a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO: 1; and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO: 1; and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO: 2; a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO: 2; and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO: 2.

[0319] [D4-2] The use according to [D1-2] or [D2-2], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0320] [D5-2] The use according to [D1-2] or [D2-2], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0321] [D6-2] The use according to [D5-2], wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0322] [D7-2] The use according to any one of [D1-2] to [D6-2], wherein n is 2 to 8.

[0323] [D8-2] The use according to any one of [D1-2] to [D6-2], wherein n is 3 to 8.

[0324] [D9-2] The use according to any one of [D1-2] to [D6-2], wherein n is 7 to 8.

[0325] [D10-2] The use according to any one of [D1-2] to [D6-2], wherein n is 7.5 to 8.

[0326] [D11-2] The use according to any one of [D1-2] to [D6-2], wherein n is 8.

[0327] [D12-2] The use according to any one of [D1-2] to [D11-2], wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

[0328] [D13-2] The use according to any one of [D1-2] to [D12-2], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553, and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0329] [D14-2] The use according to any one of [D1-2] to [D12-2], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0330] [D15-2] The use according to any one of [D1-2] to [D12-2], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0331] [D16-2] The use according to any one of [D1-2] to [D12-2], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0332] [D17-2] The use according to any one of [D1-2] to [D16-2], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained (as active ingredients) in different formulations and administered simultaneously or at different times.

[0333] [D18-2] The use according to any one of [D1-2] to [D17-2], wherein the cancer is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0334] [D19-2] The use according to [D18-2], wherein the cancer is breast cancer.

[0335] [D20-2] The use according to [D18-2], wherein the cancer is gastric cancer.

[0336] [D21-2] The use according to [D18-2], wherein the cancer is lung cancer.

[0337] [D22-2] The use according to [D21-2], wherein the lung cancer is non-small cell lung cancer.

[0338] [E1-2] A method for treating a disease, comprising administering a combination of an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor to a subject in need of treatment.

[0339] [E2-2] An anti-HER3 antibody-drug conjugate represented by the formula

[0340]

[0341] (wherein "anti-HER3 antibody" is an anti-HER3 antibody or a functional fragment thereof, the drug linker is bound to the antibody or the functional fragment thereof via a thioether bond, and n is a drug-to-antibody ratio).

[0342] [E3-2] The treatment method according to [E1-2] or [E2-2], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO: 1; a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO: 1; and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO: 1; and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO: 2; a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO: 2; and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO: 2.

[0343] [E4-2] The treatment method described in [E1-2] or [E2-2], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2.

[0344] [E5-2] The treatment method described in [E1-2] or [E2-2], wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0345] [E6-2] The therapeutic method according to [E5-2], wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.

[0346] [E7-2] The method of treatment according to any one of [E1-2] to [E6-2], wherein n is 2 to 8.

[0347] [E8-2] The method of treatment according to any one of [E1-2] to [E6-2], wherein n is 3 to 8.

[0348] [E9-2] The method of treatment according to any one of [E1-2] to [E6-2], wherein n is 7 to 8.

[0349] [E10-2] The method of treatment according to any one of [E1-2] to [E6-2], wherein n is 7.5 to 8.

[0350] [E11-2] The method of treatment according to any one of [E1-2] to [E6-2], wherein n is 8.

[0351] [E12-2] The treatment method according to any one of [E1-2] to [E11-2], wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

[0352] [E13-2] The method for treatment according to any one of [E1-2] to [E12-2], wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553 and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0353] [E14-2] The method of treatment according to any one of [E1-2] to [E12-2], wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0354] [E15-2] The method of treatment according to any one of [E1-2] to [E12-2], wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0355] [E16-2] The method of treatment according to any one of [E1-2] to [E12-2], wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0356] [E17-2] The method of treatment according to any one of [E1-2] to [E16-2], wherein the antibody-drug conjugate and the RASG12C inhibitor are contained (as active ingredients) in different formulations and administered simultaneously or at different times.

[0357] [E18-2] The method of treatment according to any one of [E1-2] to [E17-2], wherein the disease is cancer.

[0358] [E19-2] The method of treatment according to any one of [E1-2] to [E18-2], wherein the disease is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0359] [E20-2] The method of treatment according to [E19-2], wherein the disease is breast cancer.

[0360] [E21-2] The method of treatment according to [E19-2], wherein the disease is gastric cancer.

[0361] [E22-2] The method of treatment according to [E19-2], wherein the disease is lung cancer.

[0362] [E23-2] The method of treatment according to [E22-2], wherein the lung cancer is non-small cell lung cancer.

[0363] [F1-1] A pharmaceutical product comprising (i) an anti-HER3 antibody-drug conjugate and (ii) a RASG12C inhibitor, wherein the anti-HER3 antibody-drug conjugate and the RASG12C inhibitor are administered in combination, and the anti-HER3 antibody-drug conjugate and the RASG12C inhibitor are as defined in any one of [A2-1] to [A16-1] and [A2-2] to [A16-2]. [F2-1] The pharmaceutical product according to [F1-1], for the treatment of a disease defined in any one of [A18-1] to [A23-1]. [F3-1] The pharmaceutical product according to [F1-1] or [F2-1], wherein the anti-HER3 antibody-drug conjugate and the RASG12C inhibitor are contained (as active ingredients) in separate formulations and administered simultaneously or at different times. [F4-1] The pharmaceutical product according to [F1-1] or [F2-1], wherein the anti-HER3 antibody-drug conjugate and the RASG12C inhibitor are contained (as active ingredients) in the same formulation. [F5-1] The pharmaceutical product according to any one of [F1-1] to [F4-1], wherein the pharmaceutical product is a pharmaceutical composition.

[0364] [F6-1] A kit comprising (i) a first composition comprising an anti-HER3 antibody-drug conjugate and (ii) a second composition comprising a RASG12C inhibitor, wherein the anti-HER3 antibody-drug conjugate and the RASG12C inhibitor are administered in combination, and the anti-HER3 antibody-drug conjugate and the RASG12C inhibitor are as defined in any one of [A2-1] to [A16-1] and [A2-2] to [A16-2]. [F7-1] The kit described in [F6-1] for treating a disease defined in any one of [A18-1] to [A23-1]. [F8-1] The kit described in [F6-1] or [F7-1], wherein the anti-HER3 antibody-drug conjugate and the RASG12C inhibitor are contained (as active ingredients) in separate formulations and administered simultaneously or at different times. [F9-1] The kit according to [F6-1] or [F7-1], in which the anti-HER3 antibody-drug conjugate and the RASG12C inhibitor are contained (as active ingredients) in the same formulation.

[0365] [F10-1] A method for treating cancer, characterized in that an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor are administered in combination to an individual in need of treatment, wherein the anti-HER3 antibody-drug conjugate and the RASG12C inhibitor are as defined in any one of [A2-1] to [A16-1] and [A2-2] to [A16-2].

[0366] [F11-1] A pharmaceutical product comprising an anti-HER3 antibody-drug conjugate, wherein the anti-HER3 antibody-drug conjugate is administered in combination with a RASG12C inhibitor, and the anti-HER3 antibody-drug conjugate is a compound represented by the formula

[0367]

[0368] (wherein "anti-HER3 antibody" is an anti-HER3 antibody or a functional fragment thereof, each drug linker represented by the structure shown in parentheses in the formula is bound to the antibody or a functional fragment thereof via a thioether bond, and n represents the average number of drug linkers bound per antibody).

[0369] The present invention can provide a pharmaceutical product characterized by administering a combination of an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor, and / or a treatment method characterized by administering a combination of an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor to a subject.

[0370]

[0023] Figure 1 shows the amino acid sequence of an anti-HER3 antibody heavy chain (SEQ ID NO: 1). Figure 2 shows the amino acid sequence of an anti-HER3 antibody light chain (SEQ ID NO: 2). Figure 3 shows the tumor growth inhibitory effect of a group administered with HER3-ADC (1) or sotorasib alone, and a group administered with a combination of HER3-ADC (1) and sotorasib in mice subcutaneously implanted with NCI-H358 cells. Figure 4 shows the tumor growth inhibitory effect of a group administered with HER3-ADC (1) or adagrasib alone, and a group administered with a combination of HER3-ADC (1) and adagrasib in mice subcutaneously implanted with NCI-H358 cells.

[0371] Preferred embodiments for carrying out the present invention will be described below. Note that the embodiment described below shows one example of a typical embodiment of the present invention, and the scope of the present invention should not be construed as being narrow.

[0372] 1. RASG12C inhibitors

[0373] In the present invention, the term "RASG12C inhibitor" refers to a compound having inhibitory activity against a G12C mutant Ras protein, in one embodiment, a protein encoded by the KRAS, NRAS, or HRAS gene and having a G12C mutation, more preferably a protein encoded by the KRAS gene and having a G12C mutation, and is described, for example, in WO 2013 / 155223, WO 2014 / 143659, WO 2014 / 152588, WO 2014 WO 2015 / 054572, WO 2016 / 044772, WO 2016 / 049524, WO 2016 / 164675, WO 2016 / 168540, WO 2017 / 058805, WO 2017 / 015562, WO 2017 / 058728, WO 2017 / 058768, WO 2017 / 0587 No. 92, WO 2017 / 058805, WO 2017 / 058807, WO 2017 / 058902, WO 2017 / 058915, WO 2017 / 087528, WO 2017 / 100546, WO 2017 / 201161, WO 2018 / 064510, WO 2018 / 068017, WO 2018 / 119183 FRET, International Publication No. 2018 / 217651 pamphlet, International Publication No. 2018 / 140512 pamphlet, International Publication No. 2018 / 140513 pamphlet, International Publication No. 2018 / 140514 pamphlet, International Publication No. 2018 / 140598 pamphlet, International Publication No. 2018 / 140599 pamphlet, International Publication No. 2018 / 140600 pamphlet, International Publication No. 2018 / 143315 pamphlet, International Publication No. 2018 / 206539 pamphlet, International Publication No. 2018 / 218070 pamphlet,International Publication No. WO 2018 / 218071, International Publication No. WO 2019 / 051291, International Publication No. WO 2019 / 099524, International Publication No. WO 2019 / 110751, International Publication No. WO 2019 / 141250, International Publication No. WO 2019 / 150305, International Publication No. WO 2019 / 155399, International Publication No. WO 2019 / 213516, Examples of compounds that can be mentioned include compounds selected from the compounds described in International Publication Nos. 2019 / 213526, 2019 / 217307, 2019 / 215203, 2019 / 217691, 2020 / 178282, 2021 / 118877, and 2021 / 245051.

[0374] In another embodiment, the "RASG12C inhibitor" may be a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553, and JNJ-74699157, or a pharmaceutically acceptable salt thereof.

[0375] In another embodiment, the "RASG12C inhibitor" can include sotorasib (AMG510), adagrasib (MRTX849), or a pharmaceutically acceptable salt thereof.

[0376] In another embodiment, the "RASG12C inhibitor" can include sotorasib (AMG510) or a pharmaceutically acceptable salt thereof.

[0377] In another embodiment, the "RASG12C inhibitor" can include adagrasib (MRTX849) or a pharmaceutically acceptable salt thereof.

[0378] These RASG12C inhibitors can be produced by the methods described in the above-mentioned documents or by known methods.

[0379] In the present invention, the term "pharmaceutically acceptable salt" refers to a salt that is not significantly toxic and can be used as a medicine.

[0380] A compound having an acidic substituent can be converted into a salt by reacting with a base. Examples of such salts include alkali metal salts such as sodium salt, potassium salt, and lithium salt; alkaline earth metal salts such as calcium salt and magnesium salt; metal salts such as aluminum salt and iron salt; inorganic salts such as ammonium salt; amine salts such as tert-butylamine salt, tert-octylamine salt, dibenzylamine salt, morpholine salt, glucosamine salt, phenylglycine alkyl ester salt, ethylenediamine salt, N-methylglucamine salt, guanidine salt, diethylamine salt, triethylamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, chloroprocaine salt, procaine salt, diethanolamine salt, N-benzylphenethylamine salt, piperazine salt, tetramethylammonium salt, and tris(hydroxymethyl)aminomethane salt; and amino acid salts such as glycine salt, lysine salt, arginine salt, ornithine salt, glutamate, and aspartate.

[0381] A compound having a basic substituent can be converted into a salt by reacting it with an acid. Examples of such salts include hydrohalides such as hydrofluoride, hydrochloride, hydrobromide, and hydroiodide; inorganic acid salts such as nitrate, perchlorate, sulfate, and phosphate; C1-C6 alkylsulfonates such as methanesulfonate, trifluoromethanesulfonate, and ethanesulfonate; arylsulfonates such as benzenesulfonate and p-toluenesulfonate; organic acid salts such as acetate, malate, fumarate, succinate, citrate, ascorbate, tartrate, oxalate, adipate, and maleate; and amino acid salts such as glycine, lysine, arginine, ornithine, glutamate, and aspartate.

[0382] 2. Anti-HER3 antibody

[0383] In the present invention, "HER3" is synonymous with human epidermal growth factor receptor 3 (sometimes referred to as ErbB3), and is a transmembrane receptor that, together with HER1, HER2, and HER4, belongs to the epidermal growth factor receptor subfamily of receptor protein tyrosine kinases. HER3 is expressed in several types of cancer, such as breast cancer, gastrointestinal cancer, and pancreatic cancer, and is known to form heterodimers with tyrosine kinase receptors such as EGFR and HER2, thereby undergoing phosphorylation and inducing signals that inhibit cancer cell proliferation and apoptosis.

[0384] The HER3 protein used in the present invention can be directly purified from human HER3-expressing cells, or when used as an antigen, the cell membrane fraction of the cells can be used as the HER3 protein. HER3 can also be obtained by synthesizing it in vitro or by producing it in host cells through genetic engineering. Specifically, genetic engineering involves incorporating HER3 cDNA into an expression vector and then incubating the vector in a solution containing enzymes, substrates, and energy sources necessary for transcription and translation, thereby synthesizing HER3. Alternatively, the protein can be obtained by transforming other prokaryotic or eukaryotic host cells with the vector and expressing HER3. Furthermore, the genetically engineered HER3-expressing cells or cell lines expressing HER3 can also be used as HER3 protein antigens.

[0385] The RNA sequence, cDNA sequence, and amino acid sequence of HER3 are published in public databases and can be referenced by accession numbers such as AAA35979 (precursor including a signal sequence consisting of 19 amino acid residues at the amino terminal) and M34309 (NCBI).

[0386] Furthermore, HER3 also includes proteins that have an amino acid sequence in which 1 to 10 amino acids have been substituted, deleted, added and / or inserted in the amino acid sequence of the above-mentioned HER3, and that have biological activity equivalent to that of the protein.

[0387] In the present invention, the term "anti-HER3 antibody" refers to an antibody that specifically binds to HER3, and preferably has the activity of being internalized into HER3-expressing cells upon binding to HER3; in other words, an antibody that has the activity of migrating into HER3-expressing cells after binding to HER3.

[0388] The anti-HER3 antibodies used in the present invention may be derived from any species, but are preferably derived from human, rat, mouse, or rabbit. When the antibody is derived from a species other than human, it is preferably chimerized or humanized using well-known techniques. The antibodies of the present invention may be polyclonal or monoclonal, but are preferably monoclonal.

[0389] The anti-HER3 antibody used in the present invention preferably has the property of being able to target cancer cells, and preferably has the ability to recognize cancer cells, the ability to bind to cancer cells, the ability to be taken up and internalized into cancer cells, and / or cytocidal activity against cancer cells.

[0390] The binding ability of an anti-HER3 antibody to cancer cells can be confirmed using flow cytometry. The uptake of an antibody into cancer cells can be confirmed using (1) an assay in which an antibody taken up into the cell is visualized under a fluorescence microscope using a secondary antibody (fluorescently labeled) that binds to the therapeutic antibody (Cell Death and Differentiation (2008) 15, 751-761), (2) an assay in which a secondary antibody (fluorescently labeled) that binds to the therapeutic antibody is used to measure the amount of fluorescence taken up into the cell (Molecular Biology of the Cell Vol. 15, 5268-5282, December 2004), or (3) a Mab-ZAP assay in which an immunotoxin that binds to the therapeutic antibody is used, and when taken up into the cell, the toxin is released, thereby suppressing cell proliferation (Bio Techniques 28:162-165, January 2000). As an immunotoxin, a recombinant conjugated protein of the catalytic domain of diphtheria toxin and protein G can also be used.

[0391] The anti-tumor activity of an anti-HER3 antibody can be confirmed in vitro by measuring its inhibitory activity against cell proliferation. For example, a cancer cell line overexpressing the target protein of the anti-HER3 antibody is cultured, and the anti-HER3 antibody is added to the culture system at various concentrations to measure its inhibitory activity against focus formation, colony formation, and spheroid growth. In vivo, the anti-tumor activity can be confirmed, for example, by administering the antibody to nude mice transplanted with a cancer cell line highly expressing the target protein and measuring changes in the cancer cells.

[0392] Although it is preferable that the anti-HER3 antibody itself has an anti-tumor effect, since the antibody-drug conjugate of the present invention is conjugated with a compound that exerts an anti-tumor effect, the anti-HER3 antibody itself does not necessarily have an anti-tumor effect. For the purpose of specifically and selectively exerting the cytotoxicity of the anti-tumor compound on cancer cells, it is important and preferable that the anti-HER3 antibody has the property of being internalized and translocated into cancer cells.

[0393] The anti-HER3 antibodies used in the present invention can be obtained by known means. For example, they can be obtained by immunizing an animal with the antigen HER3 or any polypeptide selected from the amino acid sequence of HER3, and collecting and purifying the antibodies produced in the body, using methods commonly used in this field. The origin of the antigen is not limited to humans; animals can also be immunized with antigens derived from animals other than humans, such as mice or rats. In this case, anti-HER3 antibodies applicable to human diseases can be selected by testing the cross-reactivity of the obtained antibodies that bind to heterologous antigens with human antigens.

[0394] Alternatively, a monoclonal antibody can be obtained by fusing antibody-producing cells that produce an antibody against an antigen with myeloma cells to establish a hybridoma according to known methods (e.g., Kohler and Milstein, Nature (1975) 256, pp. 495-497; Kennet, R. ed., Monoclonal Antibodies, pp. 365-367, Plenum Press, N.Y. (1980)).

[0395] Antigens can be obtained by genetically engineering a gene encoding an antigen protein in a host cell to produce it. Specifically, a vector capable of expressing the antigen gene is prepared, introduced into a host cell to express the gene, and the expressed antigen is purified. Antibodies can also be obtained by immunizing an animal with the above-mentioned genetically engineered antigen-expressing cells or a cell line expressing the antigen.

[0396] The anti-HER3 antibody used in the present invention is preferably a recombinant antibody that has been artificially modified for the purpose of reducing heterologous antigenicity to humans, such as a chimeric antibody or a humanized antibody, or is preferably an antibody having only the genetic sequence of a human-derived antibody, i.e., a human antibody. These antibodies can be produced using known methods.

[0397] Chimeric antibodies include antibodies in which the variable and constant regions are of different species, such as chimeric antibodies in which the variable regions of a mouse- or rat-derived antibody are joined to the constant regions of a human-derived antibody (Proc. Natl. Acad. Sci. U.S.A., 81, 6851-6855, (1984)).

[0398] Examples of humanized antibodies include antibodies in which only the complementarity determining region (CDR) of a heterologous antibody has been incorporated into a human-derived antibody (Nature (1986) 321, pp. 522-525), antibodies in which not only the CDR sequence of a heterologous antibody but also some framework amino acid residues of the heterologous antibody have been grafted onto a human antibody by CDR grafting (WO 90 / 07861), and antibodies humanized using a gene conversion mutagenesis strategy (U.S. Pat. No. 5,821,337).

[0399] Human antibodies include antibodies produced using human antibody-producing mice carrying human chromosome fragments containing heavy and light chain genes of human antibodies (Tomizuka, K. et al., Nature Genetics (1997) 16, pp. 133-143; Kuroiwa, Y. et al., Nucl. Acids Res. (1998) 26, pp. 3447-3448; Yoshida, H. et al., Animal Cell Technology: Basic and Applied Aspects vol. 10, pp. 69-73 (Kitagawa, Y., Matsuda, T. and Iijima, S. eds.), Kluwer Academic Publishers, 1999; Tomizuka, K. et al., Proc. Natl. Acad. Sci. USA (2000) 97, pp. 722-727, etc. Alternatively, examples include antibodies obtained by phage display selected from a human antibody library (see, for example, Wormstone, I. M. et al., Investigative Ophthalmology & Visual Science. (2002) 43 (7), pp. 2301-2308; Carmen, S. et al., Briefings in Functional Genomics and Proteomics (2002), 1 (2), pp. 189-203; Siriwardena, D. et al., Ophthalmology (2002) 109 (3), pp. 427-431).

[0400] The anti-HER3 antibodies used in the present invention also include modified antibodies. The term "modified antibody" refers to an antibody of the present invention that has been chemically or biologically modified. Chemical modifications include those in which a chemical moiety is attached to the amino acid backbone or an N- or O-linked carbohydrate chain. Biological modifications include those that have undergone post-translational modification (e.g., addition of an N- or O-linked sugar chain, N- or C-terminal processing, deamidation, aspartic acid isomerization, methionine oxidation, etc.), and those in which a methionine residue has been added to the N-terminus by expression in a prokaryotic host cell. Also included within the meaning of such modified antibodies are those labeled to enable detection or isolation of the anti-HER3 antibody or antigen used in the present invention, such as enzyme-labeled, fluorescent-labeled, or affinity-labeled antibodies. Such modified anti-HER3 antibodies used in the present invention are useful for improving antibody stability and blood retention, reducing antigenicity, and detecting or isolating the antibody or antigen.

[0401] Furthermore, antibody-dependent cellular cytotoxicity can be enhanced by adjusting the sugar chain modification (glycosylation, defucosylation, etc.) attached to the anti-HER3 antibody used in the present invention. Techniques for adjusting antibody sugar chain modification are known, including, but not limited to, those disclosed in International Publication Nos. 99 / 54342, 00 / 61739, and 02 / 31140. Anti-HER3 antibodies used in the present invention also include antibodies with adjusted sugar chain modification.

[0402] It is known that antibodies produced in cultured mammalian cells lose the lysine residue at the carboxyl terminus of their heavy chains (Journal of Chromatography A, 705: 129-134 (1995)), and that two amino acid residues, glycine and lysine, are also deleted from the carboxyl terminus of the heavy chain, and a proline residue newly positioned at the carboxyl terminus is amidated (Analytical Biochemistry, 360: 75-83 (2007)). However, these deletions and modifications of the heavy chain sequence do not affect the antigen-binding ability or effector functions (complement activation, antibody-dependent cellular cytotoxicity, etc.) of the antibody. Therefore, the anti-HER3 antibodies used in the present invention include antibodies that have undergone such modifications and functional fragments of such antibodies, including deletions in which one or two amino acids are deleted at the carboxyl terminus of the heavy chain and amidated deletions (e.g., heavy chains in which the proline residue at the carboxyl terminus is amidated). However, as long as the antigen-binding ability and effector function are maintained, the deletions at the carboxyl termini of the heavy chains of the anti-HER3 antibodies used in the present invention are not limited to the above types. The two heavy chains constituting the anti-HER3 antibodies used in the present invention may be any one type of heavy chain selected from the group consisting of full-length heavy chains and the above-mentioned deletions, or a combination of two types of heavy chains. The quantitative ratio of each deletion may be affected by the type and culture conditions of mammalian cultured cells that produce the anti-HER3 antibodies used in the present invention, but the anti-HER3 antibodies used in the present invention preferably include those in which one amino acid residue is deleted at the carboxyl terminus of each of the two heavy chains.

[0403] As used herein, the term "functional fragment" of an antibody, also referred to as an "antigen-binding fragment" of an antibody, refers to a partial fragment of an antibody that retains antigen-binding activity, and includes Fab, F(ab')2, Fv, scFv, diabodies, linear antibodies, and multispecific antibodies formed from antibody fragments. Also included in the antigen-binding fragment of an antibody is Fab', a monovalent fragment of the variable region of an antibody obtained by treating F(ab')2 under reducing conditions. However, the antigen-binding fragment is not limited to these molecules, as long as it retains the ability to bind to an antigen. Furthermore, these antigen-binding fragments include not only those obtained by treating the full-length antibody protein molecule with an appropriate enzyme, but also proteins produced in appropriate host cells using genetically engineered antibody genes.

[0404] The isotype of the anti-HER3 antibody used in the present invention can be, for example, IgG (IgG1, IgG2, IgG3, IgG4), with IgG1 or IgG2 being preferred. Modified versions of these antibodies can also be used as anti-HER3 antibodies according to the present invention.

[0405] Anti-HER3 antibodies that can be used in the present invention include Patritumab (U3-1287), U1-59 (WO 2007 / 077028), AV-203 (WO 2011 / 136911), LJM-716 (WO 2012 / 022814), Duligotumab (MEHD-7945A) (WO 2010 / 108127), Istiratumab (MM-141) (WO 2011 / 047180), and Lumretuzumab. Examples of anti-HER3 antibodies include HER2-1b (RG-7116) (WO 2014 / 108484), setibantumab (MM-121) (WO 2008 / 100624), REGN-1400 (WO 2013 / 048883), ZW-9 (WO 2013 / 063702), and variants, active fragments, modified forms, etc. thereof, and preferred examples include patritumab and U1-59. These anti-HER3 antibodies can be produced by the methods described in the above-mentioned documents.

[0406] 3. Antibody-drug conjugates

[0407] In the present invention, the term "antibody-drug conjugate" refers to a complex in which a cytotoxic drug is bound to an antibody via a linker. Examples of antibody-drug conjugates include those described in U.S. Pat. No. 6,214,345, WO 2002 / 083067, WO 2003 / 026577, WO 2004 / 054622, WO 2005 / 112919, WO 2006 / 135371, WO 2007 / 112193, WO 2008 / 033891, WO 2009 / 100194, WO 2009 / 134976, WO 2009 / 134977, WO 2010 / 093395, WO 2011 / 093396, WO 2012 / 093397, WO 2013 / 093398, WO 2014 / 093399, WO 2015 / 093399, WO 2016 / 093399, WO 2017 / 093391, WO 2018 / 093392, WO 2019 / 093393, WO 2019 / 093394, WO 2019 / 093395, WO 2019 / 093396, WO 2019 / 093397, WO 2019 / 093398, WO 2019 / 093399, WO 2019 / 093399, WO 2019 / 093399, WO 2019 / 093399, WO 2 Examples of antibody-drug conjugates include those described in WO 2011 / 11 / 130613, WO 2011 / 130616, WO 2013 / 055993, WO 2014 / 057687, WO 2014 / 061277, WO 2014 / 107024, WO 2014 / 134457, and WO 2014 / 145090, preferably those described in WO 2014 / 057687 and WO 2014 / 061277, and more preferably those described in WO 2014 / 057687. These antibody-drug conjugates can be produced by the methods described in the above-mentioned documents.

[0408] The cytotoxic drug is not particularly limited as long as it has an antitumor effect and has a substituent or a partial structure that can be bound to a linker, and examples thereof include camptothecin, calicheamicin, doxorubicin, daunorubicin, mitomycin C, bleomycin, cyclocytidine, vincristine, vinblastine, methotrexate, cisplatin, and auristatin E. E), maytansine, paclitaxel, pyrrolobenzodiazepine, and derivatives thereof, preferably camptothecin derivatives, and more preferably exatecan derivatives. The topoisomerase I inhibitor exatecan (IUPAC name: (1S,9S)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, (chemical name: (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione)) has the formula

[0409]

[0410] It is a compound represented by the formula:

[0411] In the present invention, the term "drug linker" refers to the drug and linker moiety in an antibody-drug conjugate, in other words, the partial structure other than the antibody in an antibody-drug conjugate.

[0412] In the present invention, the term "anti-HER3 antibody-drug conjugate" refers to an antibody-drug conjugate in which the antibody in the antibody-drug conjugate is an anti-HER3 antibody. Examples of anti-HER3 antibody-drug conjugates include those described in WO 2012 / 019024, WO 2012 / 064733, and WO 2015 / 155998, and preferably those described in WO 2015 / 155998. These anti-HER3 antibody-drug conjugates can be produced by the methods described in the above-mentioned documents.

[0413] The anti-HER3 antibody-drug conjugate more preferably used in the present invention is represented by the formula

[0414] (wherein A represents the binding site to the anti-HER3 antibody or a functional fragment thereof) and an anti-HER3 antibody or a functional fragment thereof (preferably an anti-HER3 antibody) are bound via a thioether bond. This drug linker is bound to a thiol group (in other words, a sulfur atom of a cysteine ​​residue) generated at an interchain disulfide bond site (two sites between heavy chains and two sites between heavy chains and light chains) of the antibody.

[0415] The above-mentioned anti-HER3 antibody-drug conjugate, which is more preferably used in the present invention, can also be represented by the following formula:

[0416]

[0417] Here, in the formula, the "anti-HER3 antibody" is an anti-HER3 antibody or a functional fragment thereof (preferably an anti-HER3 antibody), and the drug linker is bound to the antibody via a thioether bond. Furthermore, n is synonymous with the so-called average drug binding number (DAR; Drug-to-Antibody Ratio) and indicates the average number of drug linkers bound per antibody. In the present invention, the "average number of drug linkers bound" is also called the Drug-to-Antibody Ratio (DAR), and indicates the average number of drugs (or drug linkers) bound per antibody in an antibody-drug conjugate composition. ​

[0418] The anti-HER3 antibody-drug conjugate more preferably used in the present invention is one in which the linker moiety is cleaved after the antibody has been transferred into tumor cells, and the conjugate is represented by the formula

[0419] The compound represented by the formula:

[0420] The above compound is considered to be the main component of the antitumor activity of the above anti-HER3 antibody-drug conjugate, which is more preferably used in the present invention, and has been confirmed to have a topoisomerase I inhibitory effect (Reference: Ogitani Y. et al., Clinical Cancer Research, 2016, Oct 15; 22(20):5097-5108, Epub 2016 Mar 29).

[0421] In some embodiments, the anti-HER3 antibody-drug conjugate used in the present invention is patritumab deruxtecan.

[0422] The anti-HER3 antibody-drug conjugate used in the present invention has a bystander anti-tumor effect (Reference: Ogitani Y. et al., Cancer Science (2016) 107, 1039-1046).

[0423] This bystander anti-tumor effect is exerted when the anti-HER3 antibody-drug conjugate used in the present invention is internalized into target-expressing cancer cells, and the compound is then released to exert an anti-tumor effect on nearby cancer cells that do not express the target.

[0424] This bystander anti-tumor effect is also exhibited as an excellent anti-tumor effect when the anti-HER3 antibody-drug conjugate of the present invention is used in combination with a RASG12C inhibitor.

[0425] The anti-HER3 antibody or functional fragment thereof used in the present invention preferably comprises a heavy chain comprising a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 in SEQ ID NO: 1, a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 in SEQ ID NO: 1, and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 in SEQ ID NO: 1, and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 in SEQ ID NO: 2, a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 in SEQ ID NO: 2, and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 in SEQ ID NO: 2. The antibody or functional fragment thereof (preferably an antibody) comprises a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain comprising a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 2, and even more preferably an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2, or an antibody or functional fragment thereof (preferably an antibody) from which a lysine residue at the carboxyl terminus of the heavy chain of the antibody has been deleted.

[0426] The drug linker intermediate used in the preparation of the above anti-HER3 antibody-drug conjugates is represented by the following formula:

[0427]

[0428] The drug linker intermediate can be represented by the chemical name N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]glycylglycyl-L-phenylalanyl-N-[(2-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]amino}-2-oxoethoxy)methyl]glycinamide, and can be produced with reference to the descriptions in WO 2014 / 057687 and WO 2015 / 155998, etc.

[0429] The anti-HER3 antibody-drug conjugate preferably used in the present invention can be produced by reacting the aforementioned drug linker intermediate with an anti-HER3 antibody having a thiol group (also referred to as a sulfhydryl group).

[0430] An anti-HER3 antibody having sulfhydryl groups can be obtained by methods known to those skilled in the art (Hermanson, G. T., Bioconjugate Techniques, pp. 56-136, pp. 456-493, Academic Press (1996)). For example, an anti-HER3 antibody having sulfhydryl groups in which the intra-antibody inter-chain disulfides have been partially or completely reduced can be obtained by reacting the anti-HER3 antibody with a reducing agent such as tris(2-carboxyethyl)phosphine hydrochloride (TCEP) in an amount of 0.3 to 3 molar equivalents per intra-antibody inter-chain disulfide in a buffer containing a chelating agent such as ethylenediaminetetraacetic acid (EDTA).

[0431] Furthermore, 2 to 20 molar equivalents of a drug linker intermediate can be used per anti-HER3 antibody having a sulfhydryl group to prepare anti-HER3 antibody-drug conjugates with 2 to 8 drugs bound per antibody.

[0432] The average number of drugs bound per antibody molecule in the produced anti-HER3 antibody-drug conjugate can be calculated by, for example, measuring the UV absorbance of the anti-HER3 antibody-drug conjugate and its conjugation precursor at two wavelengths, 280 nm and 370 nm (UV method), or by a method in which the antibody-drug conjugate is treated with a reducing agent, and each of the resulting fragments is quantified by HPLC measurement and then calculated (HPLC method).

[0433] Conjugation of an anti-HER3 antibody with a drug linker intermediate and calculation of the average number of drugs bound per antibody molecule in an anti-HER3 antibody-drug conjugate can be performed with reference to the descriptions in WO 2015 / 155998 and the like.

[0434] The average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate used in the present invention is preferably 2 to 8, more preferably 3 to 8, even more preferably 7 to 8, even more preferably 7.5 to 8, and even more preferably about 8. In another embodiment, the average number of drugs or drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is preferably an integer in the range of 2 to 8, more preferably 2, 4, 6, or 8, and most preferably 8.

[0435] Anti-HER3 antibody-drug conjugates can be produced with reference to the descriptions in WO 2015 / 155998 and the like.

[0436] Anti-HER3 antibody-drug conjugates for use in the present invention are known in the art. Examples of such anti-HER3 antibody-drug conjugates include, but are not limited to, DB-1310, IBI-133, SHR-A2009, AMT-562, and HMBD-501. It is also described in US2021 / 0353764 (WO2020063676), US2024 / 0026028 (WO2022078425), WO2023143365, WO2023041006, WO2023088382, WO2023125530, WO2023138635, WO2023143263, WO2023208216, WO2024077277, WO2024078449, WO2024083166 and WO2024088388, all of which are incorporated herein by reference.

[0437] 4. Medicine

[0438] Hereinafter, a pharmaceutical product and a method of treatment characterized by administering the anti-HER3 antibody-drug conjugate according to the present invention in combination with a RASG12C inhibitor will be described.

[0439] The pharmaceutical products and treatment methods of the present invention may be characterized in that the anti-HER3 antibody-drug conjugate and the RASG12C inhibitor are contained as active ingredients in separate formulations and administered simultaneously (a person skilled in the art will naturally understand that "simultaneously" may or may not mean "almost simultaneously") or at different times, or may be characterized in that the anti-HER3 antibody-drug conjugate and the RASG12C inhibitor are contained as active ingredients in a single formulation and administered.

[0440] When an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor are contained as active ingredients in separate formulations and administered at different times (even on different days), the order of administration is not particularly limited. Typically, each formulation is administered according to its respective administration method, and therefore, the administration may be the same or different. Furthermore, when each formulation is formulated separately, the administration method (administration route) of each formulation may be the same or different. Furthermore, the anti-HER3 antibody-drug conjugate and the RASG12C inhibitor do not need to be present in the body at the same time; they may be taken into the body within a certain period of time (e.g., one month, preferably one week, more preferably several days, and even more preferably one day), and the active ingredient of one of them may have disappeared from the body by the time the other is administered.

[0441] The "pharmaceutical composition" of the present invention is characterized in that the anti-HER3 antibody-drug conjugate and the RASG12C inhibitor are contained as active ingredients in a single preparation and administered.

[0442] The pharmaceutical products and treatment methods of the present invention can be used for the treatment of cancer, and are preferably used to treat breast cancer (including triple-negative breast cancer and luminal breast cancer), gastric cancer (sometimes called gastric adenocarcinoma), colon cancer (sometimes called colorectal cancer, including colon cancer and rectal cancer), lung cancer (including small cell lung cancer and non-small cell lung cancer), esophageal cancer, head and neck cancer (including salivary gland cancer and pharyngeal cancer), gastroesophageal junction adenocarcinoma, biliary tract cancer (including bile duct cancer), Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, The composition can be used to treat at least one cancer selected from the group consisting of peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, renal cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, sarcoma, osteosarcoma, and melanoma, and more preferably can be used to treat at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0443] In another aspect, the pharmaceutical products and treatment methods of the present invention can be used to treat at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

[0444] In another aspect, the pharmaceutical products and methods of treatment of the present invention can be used to treat breast cancer.

[0445] In another aspect, the pharmaceutical products and methods of treatment of the present invention can be used to treat gastric cancer.

[0446] In another aspect, the pharmaceutical products and methods of treatment of the present invention can be used to treat lung cancer.

[0447] In another aspect, the pharmaceutical products and methods of treatment of the present invention can be used to treat non-small cell lung cancer.

[0448] Cancers for which the pharmaceutical products and treatment methods of the present invention can be used preferably express HER3, and more preferably highly express HER3.

[0449] HER3 expression can be confirmed by, for example, detection at the level of the HER3 gene product (protein) by immunohistochemistry (IHC), flow cytometry, Western blotting, etc., or detection at the gene transcription level by in situ hybridization (ISH) or quantitative PCR (q-PCR). Whether HER3 is highly expressed can be determined using methods well known to those skilled in the art.

[0450] Cancers for which the pharmaceutical products and treatment methods of the present invention can be used preferably have a G12C mutation in KRAS, HRAS and / or NRAS, and more preferably have a G12C mutation in KRAS.

[0451] Determining whether a cancer contains a KRAS, HRAS, or NRAS G12C mutation can be performed by evaluating the nucleotide sequence encoding the KRAS, HRAS, or NRAS protein, by evaluating the amino acid sequence of the KRAS, HRAS, or NRAS protein, or by evaluating the characteristics of a putative KRAS, HRAS, or NRAS mutant protein. The sequence of wild-type human KRAS, HRAS, or NRAS is well known in the art (e.g., Accession No. NP203524).

[0452] Methods for detecting mutations in KRAS, HRAS, or NRAS nucleotide sequences are well known to those of skill in the art. These methods include, but are not limited to, polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assays, polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) assays, real-time PCR assays, PCR sequencing, mutant allele-specific PCR amplification (MASA) assays, direct sequencing, primer extension reactions, electrophoresis, oligonucleotide ligation assays, hybridization assays, TaqMan assays, SNP genotyping assays, high-resolution melting assays, and microarray analysis. In some embodiments, samples are evaluated for the KRAS, HRAS, or NRAS G12C mutation by real-time PCR. Real-time PCR uses a fluorescent probe specific for the KRAS, HRAS, or NRAS G12C mutation. If the mutation is present, the probe binds and fluorescence is detected. In some embodiments, the KRAS, HRAS, or NRAS G12C mutation is identified using direct sequencing of specific regions in the KRAS, HRAS, or NRAS gene (e.g., exon 2 and / or exon 3), which identifies all possible mutations in the sequenced region.

[0453] Methods for detecting mutations in KRAS, HRAS, or NRAS proteins are well known to those skilled in the art, including, but not limited to, detection of KRAS, HRAS, or NRAS mutants using binding agents (e.g., antibodies) specific for the mutant protein, protein electrophoresis and Western blotting, and direct peptide sequencing.

[0454] A variety of samples can be used in the methods for determining whether a tumor or cancer contains a KRAS, HRAS, or NRAS G12C mutation. In some embodiments, the sample is obtained from a subject with a tumor or cancer. In some embodiments, the sample is a fresh tumor / cancer sample. In some embodiments, the sample is a frozen tumor / cancer sample. In some embodiments, the sample is a formalin-fixed, paraffin-embedded sample. In some embodiments, the sample is a circulating tumor cell (CTC) sample. In some embodiments, the sample is processed into a cell lysate. In some embodiments, the sample is processed into DNA or RNA.

[0455] As used herein, a "subject" is a human or other animal in need of such treatment, and in one embodiment, a human in need of such treatment.

[0456] The antitumor effect of the pharmaceutical product and treatment method of the present invention can be confirmed, for example, by creating a model in which cancer cells are transplanted into a test animal and measuring the reduction in tumor volume and the life-prolonging effect of administering the pharmaceutical product and treatment method of the present invention.The combined effect of the anti-HER3 antibody-drug conjugate and the RASG12C inhibitor used in the present invention can be confirmed by comparing the antitumor effect with that of the antibody-drug conjugate and the RASG12C inhibitor used in the present invention when administered alone.

[0457] In addition, the antitumor effects of the pharmaceutical product and treatment method of the present invention can be confirmed in clinical trials by the Response Evaluation Criteria in Solid Tumors (RECIST) evaluation method, the WHO evaluation method, the Macdonald evaluation method, weight measurement, and other methods, and the following outcomes can be determined: complete response (CR), partial response (PR), progressive disease (PD), objective response rate (ORR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and the like. The survival rate can be determined by an index such as OS (Optical Survival Rate).

[0458] The above-mentioned method can confirm the superiority of the antitumor effects of the pharmaceutical product and treatment method of the present invention over existing pharmaceutical products and treatment methods for cancer treatment.

[0459] The pharmaceutical products and treatment methods of the present invention can slow the growth of cancer cells, suppress their proliferation, and even destroy them. These actions can relieve cancer patients from cancer-related symptoms and improve their quality of life, thereby achieving therapeutic effects while preserving the lives of cancer patients. Even if cancer cells are not destroyed, the inhibition and control of cancer cell proliferation can enable cancer patients to achieve a higher quality of life and longer survival.

[0460] The pharmaceutical product of the present invention can be applied to patients as a systemic therapy, and also can be applied locally to cancer tissues to expect therapeutic effects.

[0461] The pharmaceutical product of the present invention can be administered containing one or more pharmaceutically compatible ingredients. The pharmaceutically compatible ingredients can be appropriately selected from formulation additives and other ingredients commonly used in this field depending on the dose and administration concentration of the anti-HER3 antibody-drug conjugate and RASG12C inhibitor used in the present invention. For example, the anti-HER3 antibody-drug conjugate used in the present invention can be administered as a pharmaceutical product containing a buffer such as a histidine buffer, an excipient such as sucrose or trehalose, and a surfactant such as polysorbate 80 or 20. The pharmaceutical product containing the antibody-drug conjugate used in the present invention can be preferably used as an injection, more preferably as an aqueous injection or a lyophilized injection, and even more preferably as a lyophilized injection.

[0462] When the pharmaceutical product containing the anti-HER3 antibody-drug conjugate used in the present invention is an aqueous injection, it can be preferably administered intravenously by infusion after diluting with an appropriate diluent. Examples of the diluent include glucose solution and physiological saline, preferably glucose solution, and more preferably 5% glucose solution.

[0463] When the pharmaceutical product containing the anti-HER3 antibody-drug conjugate used in the present invention is a lyophilized injection, it is preferably dissolved in water for injection, and then diluted with an appropriate diluent at the required amount, and then administered by intravenous infusion. Examples of the diluent include glucose solution and physiological saline, preferably glucose solution, and more preferably 5% glucose solution.

[0464] The pharmaceutical product and treatment method of the present invention may further comprise a cancer therapeutic agent other than the anti-HER3 antibody-drug conjugate and RASG12C inhibitor of the present invention. The pharmaceutical product and treatment method of the present invention may also be administered in combination with other cancer therapeutic agents, thereby enhancing the anti-tumor effect. The other cancer therapeutic agents used for such purposes may be administered to a subject simultaneously with the pharmaceutical product of the present invention, separately, or consecutively, or at different administration intervals.Such cancer therapeutic agents are not limited as long as they are drugs having antitumor activity, and examples thereof include irinotecan (CPT-11), cisplatin, carboplatin, oxaliplatin, fluorouracil (5-FU), gemcitabine, capecitabine, paclitaxel, docetaxel, doxorubicin, epirubicin, cyclophosphamide, and mitomycin C. C), Tegafur / Gimeracil / Oteracil combination drug, Cetuximab, Panitumumab, Bevacizumab, Ramucirumab, Regorafenib, Trifluridine / Tipiracil combination drug, Gefitinib, Erlotinib nib), afatinib, methotrexate, pemetrexed, tamoxifen, toremifene, fulvestrant, leuprorelin, goserelin, letrozole, anastrozole, progesterone formulation, trastuzumab, pertuzumab, and lapatinib can be mentioned.

[0465] The pharmaceutical products and treatment methods of the present invention can also be used in combination with radiation therapy, for example, a cancer patient can receive radiation therapy before and / or after, or simultaneously with, treatment with the pharmaceutical product of the present invention.

[0466] The pharmaceutical products and treatment methods of the present invention can also be used as adjuvant chemotherapy in combination with surgery. The pharmaceutical products of the present invention can be administered before surgery to reduce tumor size (neoadjuvant chemotherapy, or neoadjuvant therapy), or after surgery to prevent tumor recurrence (postoperative adjuvant chemotherapy, or adjuvant therapy). The pharmaceutical products and treatment methods of the present invention can also be used as maintenance therapy.

[0467] In addition to the therapeutic uses described above, the therapeutic agent and method of the present invention can also be expected to have a preventive effect, such as suppressing the growth of and even destroying micrometastatic cancer cells. For example, they can be expected to have an effect of suppressing and destroying cancer cells present in body fluids during the metastasis process, and to suppress and destroy microscopic cancer cells immediately after implantation in any tissue. Therefore, they can be expected to have an inhibitory and preventive effect on cancer metastasis, particularly after surgical removal of cancer.

[0468] The pharmaceutical product and treatment method of the present invention can be applied to patients as a systemic therapy, and also can be applied locally to cancer tissues to achieve therapeutic effects.

[0469] The pharmaceutical products and treatment methods of the present invention are preferably used in mammals, and more preferably in humans.

[0470] The pharmaceutical product of the present invention can be administered as a pharmaceutical product containing one or more pharmaceutically compatible ingredients. The substances used in the pharmaceutical product of the present invention can be appropriately selected from formulation additives and other substances commonly used in this field, depending on the dosage and administration concentration. For example, the pharmaceutical product typically contains one or more pharmaceutical carriers (e.g., a sterile liquid). Liquids include, for example, water and oils (petroleum, animal, plant, or synthetic). Oils may be, for example, peanut oil, soybean oil, mineral oil, sesame oil, etc. Water is a more typical carrier when the pharmaceutical product is administered intravenously. Saline solutions, as well as aqueous dextrose and glycerol solutions, can also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients can be appropriately selected from those known in the art. The pharmaceutical product may also contain minor amounts of wetting or emulsifying agents, or pH buffering agents, if desired. Examples of suitable pharmaceutical carriers are described in E. W. The formulation corresponds to the mode of administration.

[0471] Various delivery systems are known and can be used to administer the pharmaceutical products of the present invention. Routes of introduction can include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, and subcutaneous routes. Administration can be, for example, by infusion or bolus injection. In certain preferred embodiments, administration of the antibody-drug conjugate is by infusion. Parenteral administration is a preferred route of administration.

[0472] In a representative embodiment, the pharmaceutical product is formulated in accordance with routine procedures as a pharmaceutical product adapted for intravenous administration to humans. Typically, pharmaceutical products for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the pharmaceutical product may also include a solubilizing agent and a local anesthetic (e.g., lignocaine) to ease pain at the injection site. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically sealed container, such as an ampoule or sachet indicating the quantity of active agent. When the pharmaceutical product is in a form to be administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical-grade water or saline. When the medicament is administered by injection, an ampoule of sterile water for injection or saline can be provided, for example, so that the ingredients can be mixed prior to administration.

[0473] The dosage of the anti-HER3 antibody-drug conjugate used in the present invention is approximately 0.001 to 100 mg / kg per administration, and is preferably 1.6 mg / kg, 3.2 mg / kg, 4.8 mg / kg, 5.6 mg / kg, 6.4 mg / kg, 8.0 mg / kg, 9.6 mg / kg, or 12.8 mg / kg per administration.

[0474] The administration interval of the anti-HER3 antibody-drug conjugate used in the present invention is once every 1 to 180 days, preferably once every week (q1w), once every 2 weeks (q2w), once every 3 weeks (q3w), or once every 4 weeks (q4w), and more preferably once every 3 weeks (q3w).

[0475] The RASG12C inhibitor used in the present invention can be administered at a single dose of 0.1 mg to 3000 mg, preferably at a single dose of 0.25 mg to 1000 mg.

[0476] The RASG12C inhibitor according to the present invention can be administered to humans at intervals of 1 to 2 times per 1 to 7 days, and preferably once a day or twice a day.

[0477] When the RASG12C inhibitor used in the present invention is adagrasib or a pharmaceutically acceptable salt thereof, examples of administration methods include, but are not limited to, the following dosage and administration methods. For example, adagrasib can be orally administered at a dose of 600 mg per dose twice a day. As an alternative dosage and administration method, adagrasib can be orally administered at a dose of 400 mg per dose twice a day. As an alternative dosage and administration method, adagrasib can be orally administered at a dose of 600 mg per dose once a day.

[0478] When the RASG12C inhibitor used in the present invention is sotorasib or a pharmaceutically acceptable salt thereof, examples of administration methods include, but are not limited to, the following dosage and administration methods. For example, sotorasib can be orally administered at a dose of 960 mg per dose once daily. As an alternative dosage and administration method, sotorasib can be orally administered at a dose of 480 mg per dose once daily. As an alternative dosage and administration method, sotorasib can be orally administered at a dose of 240 mg per dose once daily.

[0479] In this specification, unless the context requires otherwise, unless otherwise limited and technically inconsistent, terms described in the singular also include the plural, and vice versa.

[0480] The present invention will be specifically described with reference to the following examples, but the present invention is not limited to these examples. Furthermore, these examples should not be construed as limiting in any sense.

[0481] Example 1: Preparation of anti-HER3 antibody-drug conjugate According to the production method described in WO 2015 / 155998, an anti-HER3 antibody (referred to in the present invention as "anti-HER3 antibody (1)") comprising a heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 1 (FIG. 1) and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 2 (FIG. 2) was prepared by the method of the formula

[0482]

[0483] An anti-HER3 antibody-drug conjugate (referred to as "HER3-ADC(1)" in the present invention) was produced in which the anti-HER3 antibody was linked via a thioether bond to a drug linker represented by the formula: (wherein A represents the binding site to the antibody). The average number of drugs bound per antibody in HER3-ADC(1) is 7.6.

[0484] Example 2: Antitumor test (1) Mice: 5-6 week old female BALB / c nude mice (Charles River Japan) were used in the experiment. Measurement and calculation formula: In all studies, the major and minor diameters of the tumor were measured twice a week using an electronic digital caliper (CD-15CX, Mitutoyo Corp.), and the tumor volume (mm 3 ) was calculated using the following formula:

[0485] Tumor volume (mm 3 ) = 1 / 2 x major axis (mm) x [minor axis (mm)] 2

[0486] HER3-ADC (1) was diluted with ABS buffer (10 mM acetate buffer (pH 5.5), 5% sorbitol) and administered into the tail vein at a volume of 10 mL / kg.

[0487] Sotorasib was dissolved in 2% hydroxypropyl methylcellulose and 1% Tween 80 and orally administered at a volume of 10 mL / kg. Adaglasib was dissolved in 10% Captisol and 50 mM citrate buffer, pH 5.0, and orally administered at a volume of 10 mL / kg. NCI-H358 cells, a human lung cancer line purchased from the American Type Culture Collection (ATCC), were suspended in 50% Matrigel matrix (Invitrogen) and implanted subcutaneously at 3 x 10 cells into the right flank of female nude mice. 13 days after implantation, mice were randomly assigned to groups (Day 0). HER3-ADC (1) was administered intravenously at a dose of 3 mg / kg on days 0, 7, and 14. The RASG12C inhibitor was administered at a dose of 10 mg / kg once daily, five times a week for three weeks. Groups were administered each agent alone and in combination, and a vehicle-administered control group was also included.

[0488] The results of the combined use of HER3-ADC(1) and sotorasib are shown in Figure 3. The tumor growth inhibition rate (Tumor Growth Inhibition, TGI) on the final day of the study for sotorasib monotherapy was 39%. The TGI for HER3-ADC(1) monotherapy was 68%. On the other hand, the combined use of HER3-ADC(1) and sotorasib demonstrated a significantly superior tumor growth inhibition effect compared to sotorasib monotherapy (P<0.001 (calculated by Dunnett's test; the same applies below)). Furthermore, the tumor growth inhibition rate was higher (TGI, 85%) than that for HER3-ADC(1) monotherapy, demonstrating a strong combined effect. In the figure, the horizontal axis represents the number of days after cell transplantation, and the vertical axis represents tumor volume. Furthermore, anal prolapse was observed in the sotorasib-administered group on Day 35, and the mice were euthanized. No other notable findings such as weight loss were observed in any of the other single-drug or combination-administered groups. In the following evaluation examples of antitumor tests, unless otherwise specified, the tests were conducted using the same methods as in these evaluation examples.

[0489] The results of the combined use of HER3-ADC(1) and adagrasib are shown in Figure 4. The TGI with adagrasib monotherapy was 26%. The TGI with HER3-ADC(1) monotherapy was 68%. On the other hand, the combined use of HER3-ADC(1) and adagrasib demonstrated a significantly superior tumor growth inhibitory effect compared to the single-agent administration of adagrasib (P<0.001). Furthermore, the tumor growth inhibition rate was higher (TGI, 81%) than the single-agent administration of HER3-ADC(1), demonstrating a strong combined effect. No particularly notable findings, such as weight loss, were observed in any of the single-agent or combined-agent administration groups.

[0490] SEQ ID NO: 1: Amino acid sequence of the heavy chain of the anti-HER3 antibody SEQ ID NO: 2: Amino acid sequence of the light chain of the anti-HER3 antibody

Claims

1. A pharmaceutical product containing an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor.

2. The anti-HER3 antibody-drug conjugate has the formula The pharmaceutical product according to claim 1, which is an anti-HER3 antibody-drug conjugate in which a drug linker represented by the formula: (wherein A represents the binding site to the anti-HER3 antibody or a functional fragment thereof) is bound to the anti-HER3 antibody or a functional fragment thereof via a thioether bond.

3. The pharmaceutical product according to claim 1 or 2, wherein the anti-HER3 antibody or a functional fragment thereof is an antibody or a functional fragment thereof comprising: a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 in SEQ ID NO: 1; a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 in SEQ ID NO: 1; and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 in SEQ ID NO: 1; and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 in SEQ ID NO: 2; a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 in SEQ ID NO: 2; and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 in SEQ ID NO:

2.

4. The pharmaceutical product according to claim 1 or 2, wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO:

2.

5. The pharmaceutical product according to claim 1 or 2, wherein the anti-HER3 antibody is an antibody or a functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO:1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:

2.

6. The pharmaceutical product of claim 5, wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

7. The pharmaceutical product according to any one of claims 1 to 6, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 2 to 8.

8. The pharmaceutical product according to any one of claims 1 to 6, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 3 to 8.

9. The pharmaceutical product according to any one of claims 1 to 6, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7 to 8.

10. The pharmaceutical product according to any one of claims 1 to 6, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7.5 to 8.

11. The pharmaceutical product according to any one of claims 1 to 6, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is 8.

12. The pharmaceutical product of any one of claims 1 to 11, wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

13. The pharmaceutical product according to any one of claims 1 to 12, wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553 and JNJ-74699157, or a pharma- ceutically acceptable salt thereof.

14. The pharmaceutical product according to any one of claims 1 to 12, wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849) or a pharma- ceutically acceptable salt thereof.

15. The pharmaceutical product according to any one of claims 1 to 12, wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharma- ceutically acceptable salt thereof.

16. The pharmaceutical product of any one of claims 1 to 12, wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharma- ceutically acceptable salt thereof.

17. The pharmaceutical product according to any one of claims 1 to 16, characterized in that the antibody-drug conjugate and the RASG12C inhibitor are contained in different formulations and are administered simultaneously or at different times.

18. A pharmaceutical product according to any one of claims 1 to 17 for the treatment of cancer.

19. The pharmaceutical product according to any one of claims 1 to 18 for the treatment of at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

20. The pharmaceutical product according to claim 19 for the treatment of breast cancer.

21. The pharmaceutical product according to claim 19 for the treatment of gastric cancer.

22. The pharmaceutical product according to claim 19 for the treatment of lung cancer.

23. The pharmaceutical product of claim 22, wherein the lung cancer is non-small cell lung cancer.

24. The pharmaceutical product according to any one of claims 1 to 23, wherein the pharmaceutical product is a pharmaceutical composition.

25. An anti-HER3 antibody-drug conjugate for use in combination with a RASG12C inhibitor for the treatment of cancer.

26. The anti-HER3 antibody-drug conjugate has the formula The antibody-drug conjugate of claim 25, which is an anti-HER3 antibody-drug conjugate in which a drug linker represented by the formula: (wherein A represents the binding position to the anti-HER3 antibody or a functional fragment thereof) is bound to the anti-HER3 antibody or a functional fragment thereof via a thioether bond.

27. The antibody-drug conjugate according to claim 25 or 26, wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 in SEQ ID NO:1, a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 in SEQ ID NO:1, and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 in SEQ ID NO:1; and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 in SEQ ID NO:2, a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 in SEQ ID NO:2, and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 in SEQ ID NO:

2.

28. The antibody-drug conjugate according to claim 25 or 26, wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO:

2.

29. The antibody-drug conjugate of claim 25 or 26, wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO:1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:

2.

30. The antibody-drug conjugate of claim 29, wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

31. The antibody-drug conjugate according to any one of claims 25 to 30, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 2 to 8.

32. The antibody-drug conjugate according to any one of claims 25 to 30, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 3 to 8.

33. The antibody-drug conjugate according to any one of claims 25 to 30, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7 to 8.

34. The antibody-drug conjugate according to any one of claims 25 to 30, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7.5 to 8.

35. The antibody-drug conjugate according to any one of claims 25 to 30, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is 8.

36. The antibody-drug conjugate of any one of claims 25 to 35, wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

37. The antibody-drug conjugate of any one of claims 25 to 36, wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553 and JNJ-74699157, or a pharma- ceutically acceptable salt thereof.

38. The antibody-drug conjugate of any one of claims 25 to 36, wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849) or a pharma- ceutically acceptable salt thereof.

39. The antibody-drug conjugate of any one of claims 25 to 36, wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharma- ceutically acceptable salt thereof.

40. The antibody-drug conjugate of any one of claims 25 to 36, wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharma- ceutically acceptable salt thereof.

41. An antibody-drug conjugate described in any one of claims 25 to 40, characterized in that the antibody-drug conjugate and the RASG12C inhibitor are contained in different formulations and administered simultaneously or at different times.

42. The antibody-drug conjugate of any one of claims 25 to 41, wherein the cancer is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

43. The antibody-drug conjugate of claim 42, wherein the cancer is breast cancer.

44. The antibody-drug conjugate of claim 42, wherein the cancer is gastric cancer.

45. The antibody-drug conjugate of claim 42, wherein the cancer is lung cancer.

46. ​​The antibody-drug conjugate of claim 45, wherein the lung cancer is non-small cell lung cancer.

47. A method for treating a disease, comprising administering an anti-HER3 antibody-drug conjugate and a RASG12C inhibitor in combination to a subject in need of treatment.

48. The anti-HER3 antibody-drug conjugate is represented by the formula The method of claim 47, which is an anti-HER3 antibody-drug conjugate in which a drug linker represented by the formula: (wherein A represents the binding site to the anti-HER3 antibody or a functional fragment thereof) is bound to the anti-HER3 antibody or a functional fragment thereof via a thioether bond.

49. The method of treatment according to claim 47 or 48, wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO:1; a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO:1; and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO:1; and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO:2; a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO:2; and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO:

2.

50. The therapeutic method described in claim 47 or 48, wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO:

2.

51. The method of treatment according to claim 47 or 48, wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO:1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:

2.

52. The method of treatment of claim 51, wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

53. A therapeutic method according to any one of claims 47 to 52, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 2 to 8.

54. A therapeutic method according to any one of claims 47 to 52, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 3 to 8.

55. A therapeutic method according to any one of claims 47 to 52, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7 to 8.

56. A therapeutic method according to any one of claims 47 to 52, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is in the range of 7.5 to 8.

57. A therapeutic method according to any one of claims 47 to 52, wherein the average number of drug linkers bound per antibody in the anti-HER3 antibody-drug conjugate is 8.

58. The method of treatment of any one of claims 47 to 57, wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

59. The method of treatment of any one of claims 47 to 58, wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553 and JNJ-74699157, or a pharma- ceutically acceptable salt thereof.

60. A method of treatment according to any one of claims 47 to 58, wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849) or a pharma- ceutically acceptable salt thereof.

61. The method of treatment of any one of claims 47 to 58, wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharma- ceutically acceptable salt thereof.

62. The method of treatment of any one of claims 47 to 58, wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharma- ceutically acceptable salt thereof.

63. A therapeutic method according to any one of claims 47 to 62, characterized in that the antibody-drug conjugate and the RASG12C inhibitor are contained in different formulations and administered simultaneously or at different times.

64. A therapeutic method according to any one of claims 47 to 63, wherein the disease is cancer.

65. A method for the treatment of any one of claims 47 to 64, wherein the disease is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colon cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

66. The method of treatment of claim 65, wherein the disease is breast cancer.

67. The method of treatment described in claim 65, wherein the disease is gastric cancer.

68. The method of claim 65, wherein the disease is lung cancer.

69. The method of claim 68, wherein the lung cancer is non-small cell lung cancer.

70. The anti-HER3 antibody-drug conjugate is represented by the formula (wherein "anti-HER3 antibody" is an anti-HER3 antibody or a functional fragment thereof, the drug linker is bound to the antibody or a functional fragment thereof via a thioether bond, and n is a drug-to-antibody ratio).

71. The pharmaceutical product of claim 70, wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO:1; a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO:1; and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO:1; and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO:2; a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO:2; and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO:

2.

72. The pharmaceutical product according to claim 70, wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO:1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO:

2.

73. The pharmaceutical product of claim 70, wherein the anti-HER3 antibody is an antibody or a functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO:1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:

2.

74. The pharmaceutical product of claim 73, wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

75. The pharmaceutical product of any one of claims 70 to 74, wherein n is 2 to 8.

76. The pharmaceutical product of any one of claims 70 to 74, wherein n is 3 to 8.

77. The pharmaceutical product of any one of claims 70 to 74, wherein n is 7 to 8.

78. The pharmaceutical product of any one of claims 70 to 74, wherein n is 7.5 to 8.

79. The pharmaceutical product of any one of claims 70 to 74, wherein n is 8.

80. The pharmaceutical product of any one of claims 70-79, wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

81. The pharmaceutical product of any one of claims 70 to 80, wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553, and JNJ-74699157, or a pharma- ceutically acceptable salt thereof.

82. The pharmaceutical product of any one of claims 70 to 80, wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849) or a pharma- ceutically acceptable salt thereof.

83. The pharmaceutical product of any one of claims 70 to 80, wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharma- ceutically acceptable salt thereof.

84. The pharmaceutical product of any one of claims 70 to 80, wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharma- ceutically acceptable salt thereof.

85. The pharmaceutical product described in any one of claims 70 to 84, characterized in that the antibody-drug conjugate and the RASG12C inhibitor are contained in different formulations and are administered simultaneously or at different times.

86. A pharmaceutical product according to any one of claims 70 to 85 for the treatment of cancer.

87. The pharmaceutical product according to any one of claims 70 to 86 for the treatment of at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

88. The pharmaceutical product of claim 87 for the treatment of breast cancer.

89. The pharmaceutical product of claim 87 for the treatment of gastric cancer.

90. The pharmaceutical product of claim 87 for the treatment of lung cancer.

91. The pharmaceutical product of claim 90, wherein the lung cancer is non-small cell lung cancer.

92. The pharmaceutical product of any one of claims 70 to 91, wherein the pharmaceutical product is a pharmaceutical composition.

93. The anti-HER3 antibody-drug conjugate is represented by the formula (wherein "anti-HER3 antibody" is an anti-HER3 antibody or a functional fragment thereof, the drug linker is bound to the antibody or a functional fragment thereof via a thioether bond, and n is a drug-to-antibody ratio).

94. The antibody-drug conjugate according to claim 93, wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 in SEQ ID NO:1, a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 in SEQ ID NO:1, and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 in SEQ ID NO:1; and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 in SEQ ID NO:2, a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 in SEQ ID NO:2, and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 in SEQ ID NO:

2.

95. The antibody-drug conjugate of claim 93, wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO:1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO:

2.

96. The antibody-drug conjugate of claim 93, wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO:1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:

2.

97. The antibody-drug conjugate of claim 96, wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

98. The antibody-drug conjugate of any one of claims 93 to 97, wherein n is 2 to 8.

99. The antibody-drug conjugate of any one of claims 93 to 97, wherein n is 3 to 8.

100. The antibody-drug conjugate of any one of claims 93 to 97, wherein n is 7 to 8.

101. The antibody-drug conjugate of any one of claims 93 to 97, wherein n is 7.5 to 8.

102. The antibody-drug conjugate of any one of claims 93 to 97, wherein n is 8.

103. The antibody-drug conjugate of any one of claims 93 to 102, wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

104. The antibody-drug conjugate of any one of claims 93 to 103, wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553 and JNJ-74699157, or a pharma- ceutically acceptable salt thereof.

105. The antibody-drug conjugate of any one of claims 93 to 103, wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharma- ceutically acceptable salt thereof.

106. The antibody-drug conjugate of any one of claims 93 to 103, wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharma- ceutically acceptable salt thereof.

107. The antibody-drug conjugate of any one of claims 93 to 103, wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharma- ceutically acceptable salt thereof.

108. An antibody-drug conjugate described in any one of claims 93 to 107, characterized in that the antibody-drug conjugate and the RASG12C inhibitor are contained in different formulations and administered simultaneously or at different times.

109. The antibody-drug conjugate of any one of claims 93 to 108, wherein the cancer is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colon cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

110. The antibody-drug conjugate of claim 109, wherein the cancer is breast cancer.

111. The antibody-drug conjugate of claim 109, wherein the cancer is gastric cancer.

112. The antibody-drug conjugate of claim 109, wherein the cancer is lung cancer.

113. The antibody-drug conjugate of claim 112, wherein the lung cancer is non-small cell lung cancer.

114. An anti-HER3 antibody-drug conjugate having the formula (wherein "anti-HER3 antibody" is an anti-HER3 antibody or a functional fragment thereof, the drug linker is bound to the antibody or a functional fragment thereof via a thioether bond, and n is a drug-to-antibody ratio).

115. The method of claim 114, wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising: a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO:1; a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO:1; and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO:1; and a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO:2; a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO:2; and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO:

2.

116. The method for treatment according to claim 114, wherein the anti-HER3 antibody or a functional fragment thereof is an antibody or a functional fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO:

2.

117. The therapeutic method according to claim 114, wherein the anti-HER3 antibody or functional fragment thereof is an antibody or functional fragment thereof comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO:1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:

2.

118. The method of treatment of claim 117, wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

119. The method of treatment of any one of claims 114 to 118, wherein n is 2 to 8.

120. The method of treatment of any one of claims 114 to 118, wherein n is 3 to 8.

121. The method of treatment of any one of claims 114 to 118, wherein n is 7 to 8.

122. The method of treatment of any one of claims 114 to 118, wherein n is 7.5 to 8.

123. The method of treatment of any one of claims 114 to 118, wherein n is 8.

124. The method of treatment of any one of claims 114 to 123, wherein the anti-HER3 antibody-drug conjugate is patritumab deruxtecan.

125. The method of treatment of any one of claims 114 to 124, wherein the RASG12C inhibitor is a compound selected from the group consisting of LY3537982, AZD4625, sotorasib (AMG510), adagrasib (MRTX849), JDQ443, GDC-6036, BI1,823,911, D1553, and JNJ-74699157, or a pharma- ceutically acceptable salt thereof.

126. The method of treatment of any one of claims 114 to 124, wherein the RASG12C inhibitor is sotorasib (AMG510), adagrasib (MRTX849), or a pharma- ceutically acceptable salt thereof.

127. The method of treatment of any one of claims 114 to 124, wherein the RASG12C inhibitor is sotorasib (AMG510) or a pharma- ceutically acceptable salt thereof.

128. The method of treatment of any one of claims 114 to 124, wherein the RASG12C inhibitor is adagrasib (MRTX849) or a pharma- ceutically acceptable salt thereof.

129. A therapeutic method according to any one of claims 114 to 128, characterized in that the antibody-drug conjugate and the RASG12C inhibitor are contained in different formulations and administered simultaneously or at different times.

130. A method of treatment according to any one of claims 114 to 129, wherein the disease is cancer.

131. The method of treatment according to any one of claims 114 to 130, wherein the disease is at least one cancer selected from the group consisting of breast cancer, gastric cancer, colon cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, renal cancer, and sarcoma.

132. The method of treatment described in claim 131, wherein the disease is breast cancer.

133. The method of treatment described in claim 131, wherein the disease is gastric cancer.

134. The method of treatment described in claim 131, wherein the disease is lung cancer.

135. The therapeutic method of claim 134, wherein the lung cancer is non-small cell lung cancer.

Citation Information

Patent Citations

  • Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof

    US20210353764A1

  • Anti-her3 antibody and Anti-her3 antibody-drug conjugate and medical use thereof

    US20240026028A1

  • Immunoglobulin variants

    US5821337A

  • Lysosomal enzyme-cleavable antitumor drug conjugates

    US6214345B1

  • CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR

    WO1990007861A1

Cited By

  • Pharmaceutical composition for treatment and / or prevention of cancer

    CN123036312A

  • Pharmaceutical composition for treating and / or preventing cancer

    WO2025206085A1